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ABSTRACT 
Bovine Viral Diarrhoea Virus (BVDV) is a significant pathogen associated with 
gastrointestinal, respiratory, and reproductive diseases of cattle worldwide. The 
ability of BVDV to cross the placenta during early pregnancy can result in the birth of 
persistently infected (PI) calves, which are capable of shedding large quantities of 
virus throughout their lives and are considered the primary reservoirs for BVDV. PI 
animals do not show antibody response, and diagnostic tests such as virus isolation, 
immunohistochemistry (IHC), Antigen-Capture ELISA (ACE), and RT-PCR are used 
in their detection. Control efforts based on the  identification and  elimination of PI 
animals have been successful in a number of countries around the world. In Italy, 
little research has been done concerning BVDV prevalence and  at this time no 
compulsory/voluntary control program exists. In order to investigate the 
seroprevalence and to identify PI animals in Central Italy, a serological survey on 
1,929 unvaccinated Holstein Friesian animals from 21 farms from the Marche, 
Umbria and Lazio regions was carried out. Sera samples were tested to detect 
BVDV antibodies using a commercial ELISA kit (Antibody BVDV IDEXX HerdCheck). 
In order to detect PI cattle, all young (2 years old) and seronegative animals were 
tested individually using a commercial ACE (Serum/ACE BVDV IDEXX HerdCheck) 
and a RT-PCR protocol using pooled sera samples. In order to compare two 
different epidemiological situations, a short survey of 2 months was carried out at the 
Veterinary Diagnostic Laboratory of the Colorado State University (Rocky Ford, 
Colorado, USA) where a BVD voluntary program based on the identification and 
elimination of PI animals has been implemented. The protocol was carried out 
testing surnatants of ear-notches individually by ACE (ACE BVDV IDEXX, USA) 
derived from positive pools previously tested by RT-PCR. A total number of 14,508 
samples were received, conforming 360 pools with an average number of 40 
samples each one.    
The results obtained in the serological survey of Central Italy demonstrated a 
total seroprevalence of 26.43%, meanwhile seroprevalences of 20.35%, 24.92% and 
31.66% were observed in Umbria, Marche and Lazio regions respectively. These 
results showed the presence of BVDV infection with low prevalence. According to 
the age, 5.33% and 85.28% of animals younger and older than 2 years old 
respectively were positive. Only 10% (2/20) of farms showed recent infection of 
BVDV due to the presence of seropositive animals younger than 24 months old. All 
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seronegative / young animals tested (No. 490) were negative with the Serum/ACE  
using both, the standard and  the overnight incubation methods with the intent to 
improve the sensitivity of the test, as well as by pooled RT-PCR. As additional 
Serum/ACE kit evaluation, 10-fold serial dilutions of BVDV TMV-2 strain in BVDV 
negative serum were tested, and positive results were seen in a 10-3 dilution 
confirming its validity. Therefore, no PI animals were  identified in our research. 
Several factors such as the low PI prevalence, intermittence of BVDV excretion, the 
presence of a low percentage of PI animals that do not show detectable viral titers, 
along with the changing levels of viremia in PI animals must be considered. Our 
results demonstrate the presence of BVDV infection even in the absence of PI 
animals, illustrating the possible important role of  transiently infected (TI) animals in 
the long term circulation of BVDV. Probably risk of indirect or external avenues of 
transmission must be considered due to the presence of on-going infections. In 
addition, the current herd management practices and low cattle density in Central 
Italy may be contributors to the low presence of  PI animals. On the basis of these 
results the BVDV spread in Central Italy does not appear critical. The application of 
other diagnostic techniques such as IHC, RT-PCR and ACE using buffy coat and/or 
ear notches samples to detect the presence of PI animals is strongly recommended. 
In other hand and following the protocol of the Colorado State University, 15 
Hereford of 4 months old animals were detected as PI animals, representing a total 
prevalence of 0.1%. This prevalence has been described everywhere, ranging from 
0.5 to 2%. The methodology used  offered a low-cost and highly sensitive  system to 
detect BVDV infected animals.  
Important differences as the number of animals sampled, the absence/ presence of 
a Control Program, the different samples used in each survey (serum vs. ear notch), 
differences in size, density and management, as well as the role of the presence of 
wild animals in the Colorado State are factors that must be considered between the 
different results observed in  both surveys.  
 
Keywords: Bovine Viral Diarrhoea Virus, Diagnostic Techniques, Persistent Infected 
Animals, Pooled Sera Samples, RT-PCR, Antigen Capture ELISA.  
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1. DEFINITION  
The Bovine Viral Diarrhoea (BVD) is an infectious disease associated with 
pathology in several physiologic systems including reproductive, respiratory, 
gastrointestinal, circulatory, immunologic lymphatic, musculoskeletal, integumentary 
and central nervous (Brock KV., 2004a). BVD causes several sinology as pyrexia, 
diarrhoea, oculo-nasal discharge, depression, lymphopenia, thrombocytopenia, 
abortion, pneumonia and several secondary infections (Brock KV, 2004b). The virus 
has the ability to cause transplacental infection resulting in different outcomes 
depending on the stage of gestation at which the infection takes place, leading the 
presence of foetal death, malformation, acute syndromes of the neonate, immune 
tolerance and lifelong viral persistence (Peterhans E. et al., 2003). Because BVDV is 
an endemic disease in cattle populations in most parts of the world and due to its 
high prevalence and persistence, in combination with the negative effects on 
reproduction and the general health condition in dairy and beef herds, it is 
considered  one of the most significant infectious pathogens in the livestock  industry 
(Moennig V. et al., 2005a and 2006). 
 
2. HISTORY  
A disease of unknown origin affecting cattle was first described in the 1940s 
(Olafson P. et al. 1947). In western Canada, “ X disease”  was characterized by 
fever, watery and bloody diarrhoea, dehydration, tachypnea, anorexia, nasal 
discharge, hypersalivation and development of ulcers of the mucous membranes. 
Post-mortem findings were extensive, including erosive lesions in the respiratory and 
digestive tracts, together with a general enlargement of the lymph nodes. Later, in 
the Cornell University was reported an outbreak of an apparently new transmissible 
disease in cattle during the spring and summer of 1946 (Olafson P., et al. 1947; 
Brock VK., 2004a). The clinical signs and post-mortem findings were similar to those 
observed in “ X disease” . However, Olafson observed that this new disease was 
reproducible, causing high mortality rates and it was associated with additional signs 
of respiratory disease, leucopoenia, drop in milk production and increased abortion 
rates. Finally in 1957, researchers isolated and cultured a virus from a similar case 
of infection accompanied with severe erosions and haemorrhages of the intestinal 
tract, which later was called  mucosal disease (MD) (Underdahl NR,. et al., 1957). In 
this way, the unknown disease became Bovine Viral Diarrhoea (BVD). 
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By the end of the 1960, Scientifics speculated that MD and BVD disease were 
the same disease with minor variations. Then between 1960s and 1970s the 
research into the pathogenesis of the MD complex (BVD-MD) was focused on 
experimental infections, observing that abortions and teratogenic disorders were 
associated with intrauterine BVD virus (BVDV) infections. Such experiments also led 
to the understanding that neonatal calves congenitally infected with BVDV usually 
did not survive for more than a few months and eventually succumbing to what was 
previously described as chronic MD. These calves were discovered to be 
persistently infected (PI) with BVDV, and most importantly, PI calves were found to 
have an immunological abnormality because they did not produce detectable 
antibodies against BVDV (Brock KV., 2003).  
At 1980s, BVDV was classified as a Pestivirus, together with border disease 
virus (BDV) and classical swine fever virus (CSFV). Cases of severe clinical 
disease, with severe gross and histological lesions caused by BVDV, were arbitrarily 
designated as MD. In contrast, the mild disease associated with minimal clinical 
changes from which BVD virus was isolated was called BVD. Until 1984, the 
researchers were able to reproduce classical MD with BVDV. Mucosal disease was 
replicated when a cytopathic BVD-MD virus was inoculated into a PI animal. It was 
subsequently established that MD occurs only in PI animals after super-infection 
with a strain of cytophatic  BVDV that is antigenically similar to the non-cytophatic  
BVDV (Tautz N., et al., 1998; Larson RL., 2006).  
After the initial 30-year period, the characterization of BVDV as an RNA virus 
expected that mutation and variation would occur, and lately, the antigenic, genetic 
and pathogenic variation of the virus has been recognized. With the establishment of 
the major foundations (pathogenesis and biology) of BVDV, rapid advancements in 
the area of diagnostic detection including PCR, Real-Time PCR, 
immunohistochemistry and molecular epidemiology improve its research. 
Unfortunately, the adaptation to BVDV to cattle and the ability to cause persistent 
infections have given to the virus advantage to survive (Peterhans E. et al., 2003; 
Brock VK., 2004).  
 
3. ETIOLOGY 
BVDV is a member of the Pestivirus genus, belonging to the family 
Flaviviridae, which also includes border disease virus (BDV) and classical swine 
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fever virus (CSFV), three viruses that cause important financial losses to the 
livestock industry (Hornberg A., et al, 2008). Pestiviruses are small enveloped 
viruses of 40 to 60 nm diameter (Fig. 1). The genome consists of a single positive 
stranded RNA of about 12.5 kb (Fig. 2) (Tautz N., et al., 2003). The single open 
reading frame (ORF) is flanked by 5′ and 3′ untranslated regions (UTR). The 5’  
terminus of the genome is not capped, and the initiation of translation is mediated by 
an internal ribosomal entry site.  The 5′ end of the genome, an UTR of about 370 
bases, is immediately followed by a single ORF encoding for a unique polyprotein 
which is cleaved and matured into structural and non structural proteins of about 
4000 amino acids (Murray CL., et al, 2007).  
 
   
 
                                                                       Fig.2. Genome organization and polyprotein processing of pestivirus 
 
The polyprotein is processed by cellular and viral proteases into mature viral 
proteins, designated from the N terminus as structural (Npro, C, Erns, E1, E2, p7) and 
non-structural proteins (NS2, NS3, NS4A, NS4B, NS5A, and NS5B) (Fig. 2).  Npro, 
the first viral protein translated in the genome, possesses an auto-proteolytic activity 
responsible for cleavage at its own C terminus. Next  encoded in the polyprotein are 
the viral structural proteins, capsid (C) and three virion-associated glycoproteins, 
Erns, E1, and E2. Several reports have shown that E2 is a major target of neutralizing 
antibodies, suggesting a significant role in receptor-mediated viral entry (Pankraz A., 
et al., 2005). Erns has been reported to have intrinsic RNase activity, but its role in 
viral infection remains ambiguous. The BVDV genome encodes non-structural (NS) 
proteins, which are principally  involved in viral replication (Sun JH.,  et al., 2003). 
BVDV uses a strategy similar to that of other positive-strand RNA viruses to 
replicate (Fig. 3). Upon infection of cells, the genomic RNA serves as mRNA and is 
translated to produce the viral nonstructural proteins which are necessary for BVDV 
replication. Viral RNA replication is initiated by synthesizing a full-length minus-
strand RNA complementary to the genomic plus-strand RNA. This minus strand then 
Fig. 1. Pestivirus structure
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serves as the preferred template for synthesis of additional plus-strand RNA 
molecules. Both minus and plus-strand viral RNAs can be detected at 4 h post-
infection. Progeny virus can be detected as early as 8 h. Flavivirus RNA synthesis is 
localized to endoplasmic reticular membranes in the peri-nuclear site of infected 
cells (Lee YM.,  et al, 2005; Murray CL., et al, 2007).  
 
 
                         
  
                                             Fig. 3. General Pestivirus replication cycle 
 
Mutations are frequent in RNA viruses  and have been estimated as occurring 
about once per viral cycle for 10 kb, which is approximately the size of the BVDV 
genome. This means that any base in the viral genome is expected to undergo 
mutation once in every 10,000 replications of the viral RNA and it is attributable to 
the error-prone viral RNA polymerases responsible for replication of viral RNA (Bolin 
SR., et al., 2004). Genetic recombinations may also arise when two different virions 
co-infect the same cell, allowing crossing-over between two genomes and resulting 
in a hybrid RNA (Desport M., et al., 1998). Mutated viruses may be viable but 
disadvantaged as compared to the parent virus, but some mutations may result in 
the modification of viral antigens which will eventually allow to escape the host’ s 
immune response (Bolin SR., et al., 2004). 
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3.1. BVDV Genotypes  and  Biotypes 
On the basis on their ability to induce microscopically visible changes 
(vacuolization and lysis) in host cells in vitro, BVDV isolates are divided into two 
biotypes (Fig. 4) (Birk AV., et al., 2008; Neill JD., et al., 2008). Cytopathic (CP) 
isolates cause changes in host cells, while  noncytopathic (NCP) isolates do not 
cause cellular changes. Both biotypes of BVDV infect cattle and cause disease, but 
only the NCP biotype causes persistent infections (Kelling CL., 2004). The molecular 
basis of the CP effect is the synthesis of an additional protein of 80 kDa (called NS3 
protein) produced in cells infected by a CP virus (Donis RO., et al., 1991). Biotypes 
apparently behave differently in vivo. NCP strains have a tropism for leucocytes, 
lymphoid organs and the respiratory tract, while CP strains are more or less 
restricted to the digestive tract. With the exception of  MD cases, the majority of 
BVDV isolates from the fields are of the NCP biotype (Bezek DM., et al., 1994). CP 
strains would accidentally derive from this reservoir by mutation and would constitute 
an epidemiological dead-end. Lately, Ridpath (2006a) has suggested a third 
classification of a NCP BVDV strain, proposed as lymphocytopathic biotype which 
correlates with high virulence in acute infections in vivo. This biotype is able to 
shows only visible change in cultured lymphoid cells, concluding that belongs to a 
low  virulence NCP biotype.  
 
                   
 
Fig. 4. Infected  MDBK  cells  with NCP (left) and CP (right) BVDV. Arrows indicate  the cytoplasmic 
vacuolization induced by BVDV CP strains.  
 
On the basis of the nucleotide sequence of the 5’ UTR, two genotypes of 
BVDV have been described (Ridpath JF., 2003; Vilcek S., et al., 2005). Genotype 1 
includes the classic BVDV isolates, which are commonly used in laboratory 
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reference and vaccine strains. Type 1 is subdivided into two types 1a and 1b, but a 
recent study indicated that BVDV could be clustered into 11 phylogenetic groups 
(Vilcek S., et al., 2001). In other hand, genotype 2 comprises the BVDV strains 
associated with high mortality acute and per-acute infections, thrombocytopenia and 
haemorrhaging. Although both genotypes cause disease, the clinically severe, acute 
BVDV infections are caused by NCP type 2 BVDV (Giangaspero M.,  et al., 2008).  
In cattle populations BVDV-1 strains are predominant in most part of the 
world, whereas BVDV-2 is recognized as the cause of severe acute haemorragic 
disease in North America (Pellerin C., et al., 1994), being recently reported in 
Europe and Asia with low virulence (Letellier C., et al., 1999; Luzzago C., et al., 
2001). In Italy,  BVDV-1 is the predominant and most wide distributed genotype in 
the north of the country, where 30% of the bovine population is concentred. The 
BVDV-1b is the most frequently isolated, followed by groups c, d and e (Luzzago C. 
et al., 2001; Falcone E. et al., 2001 and 2003). Recently, Giammarioli M. et al., 
(2008) have reported that from 88 BVD viruses found throughout Italy, genetic 
studies based on the 5'-UTR showed the presence of subgenotypes BVDV-1a, 1b, 
1d, 1e, 1f , 1g and 1h. In case of  BVDV-2 genotype, it has been isolated from 2 
healthy animals from a farm in the northern Italy where a several outbreak of BVDV 
was present few months before the screening (Luzzago C. et al., 2001), and in a 
several outbreak originated for the use of Herpesvirus-1 Modified Lived Vaccine 
(MLV) contaminated with BVDV-2 strain (Falcone E. et al., 1999). The presence of 
BVDV-2a has also been demonstrated in 5 of 88 BVD viruses found  throughout Italy  
(Giammarioli M., et al., 2008). 
 
4. EPIDEMIOLOGY  
 Transmission of BVDV occurs both horizontally and vertically (Fig. 5) (Lindberg 
A., et al.,  2005 and 2006). In an infected herd, there are two principally different 
sources of virus: PI animals and animals that undergo a transient infection (TI) (Fig. 
5). Direct contact between an infected or PI animal and susceptible animal is 
considered the principal route of transmission. The horizontal transmission of BVDV 
may be direct or indirect via inhalation or ingestion of virus contaminated materials. 
Horizontal transmission occurs mainly by contacts with virus-shedding,  but PI and 
TI animals excrete the virus in different amounts (Houe H., 1995). 
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The probability of transmitting BVDV by other means than nose-to-nose 
contact is dependent on the dose and on the means of contact. The virus persists in 
the environment for more than 2 weeks and can be excreted by saliva, ocular or 
nasal secretions, urine, semen, uterine secretions, amniotic fluid, placenta and 
vaginal mucus. Infected bulls can shed BVDV in semen for prolonged periods, and 
cattle have been infected following insemination with frozen semen from these 
animals (Houe H., 1995; Gard JA., et al., 2007). Experimental studies have shown 
that various equipment as nose tongs and rubber stopper on a vaccine vial 
contaminated serve as a vector for infection (Fray MD.,  et al., 1998; Lindberg A., et 
al.,  2006). 
In other hand, BVDV passes vertically by transplacental infection from 
infected dams to the foetus. BVDV uses the productive system  to maintain and 
spread itself in the cattle population by inducing immunotolerance following foetal 
infection, resulting in birth of PI calves that are considered the most important source 
of infection (Loneragan GH., et al., 2005).  
 
                             
 
 
 
Fig. 5. Relative role of TI vs. PI animals as source of virus for horizontal and vertical transmission of BVDV and 
the possible outcomes within an infected herd  (Lindberg A., et al., 2005). 
 
4.1. Persistently Infected animals (PI) 
 
The definition of BVDV PI animal is one that BVD virus has been isolated 
from peripheral blood leukocytes or serum in two separate occasions at least 3 
weeks apart (Brodersen BW., 2004). The prevalence of BVDV PI cattle has typically 
been observed in the range of 0.5% to 2% (Brock KV., 2003; Peterhans E., et al., 
2003; Smith DR., et al., 2004), although the prevalence of PI within herds is variable. 
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The age-specific prevalence of PI is greatest at birth and decreases with age.  
Approximately  50% of BVDV PI cattle will die during the first year of life (Smirnova 
NP.,  et al., 2008). 
PI animals play a substantially larger role in transmitting the virus than TI 
animals do. They shed virus in high concentrations in all bodily fluids during their 
entire life (Brock KV., 2003; Muñoz-Zanzi CA., et al., 2000 and 2003). The blood of 
PI animals can contain up to 107 TCID
50
/mL BVDV (Perry GH., 2007). However, 
empirical evidence supports the importance of PI animals for within-herd spread in 
that the infection essentially stops when PI animals are removed, which makes it 
possible to clear infected herds from the virus without taking special measures 
(Lindberg A., et al., 2005).  
 The effect of the massive doses of virus shed by PI animals on within-herd 
spread of BVDV is evident from studies showing that airborne transmission can 
occur within buildings, and tools as equipment  and pens where PI animals have 
been housed can (for a limited period of time) carry a sufficient dose of live virus for 
susceptible animals to seroconvert (Niskanen R. and Lindberg A., 2003). In 
comparison to TI cattle, horizontal transmission of virus from PI animals to 
susceptible cattle is more efficient. 
Some reports have shown that after PI animals are born, more than 90% of 
cattle in the herd before 3±4 months of age get infected. This was also seen in the 
study by Moerman A. et al. (1994), where all susceptible cattle that came into 
contact with a PI animal became seropositive within 3 months. In another study, 
seronegative animals seroconverted within 5 months after the introduction of a PI 
animal and at short distances, the animals had seroconverted within 2 months, 
whereas at longer distances the time of seroconversion was more undefined.  
In beef herds, suckling calves are commonly in contact with the breeding herd 
during early gestation when the foetus is susceptible to BVDV persistent infection 
before 125 days of gestation. As a result, PI  suckling calves are considered the 
primary source of BVDV infection in breeding herds, causing decreased conception 
rates, loss of pregnancy, pre-weaning mortality, and induction of PI calves in the 
next year’ s calf crop (Ezanno P., et al, 2008). 
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 Cattle transiently infected (TI) 
 
TI animals play a less significant role in persistence and spread in BVDV 
herds, but do affect the general health of herd. TI cattle can be the primary source 
for introduction of BVDV and initiation of PI, but they are inefficient sources of 
horizontal virus transmission (Brodersen BW., 2004; Smith DR.  et al., 2004). The 
probability of horizontal transmission during a contact with a TI animal stands in 
sharp contrast to that of PI animals, due to the intermittent shed of relatively low 
amounts of virus (Niskanen R, Lindberg A., 2003) . There are experimental results 
that indicate that the primary infection may be only rarely propagated and TI 
animals, unless they are in early pregnancy, are the end for the infection (Lindberg 
A. and Houe H., 2005). The probability of vertical spread resulting from a TI is much 
higher than the probability of horizontal spread. In fact, most new PI detected in an 
infected herd will be the result of TI in dams with a normal immune response. 
However, there are some reports that suggest that TI can circulate for long periods 
of time (10 months or more) even in the absence of identified PI animals (Moerman 
A., et al., 1993). In two studies, the virus circulated for 2±2.5 years although there 
were no PI  animals present and no direct contact with PI cattle was established 
(Moen A. et al., 2005).  
The length of the contact can be permanent, meaning that the infectious 
animal is permanently introduced into the herd, or transient, where the infectious 
animal is in contact with other herds for a limited period of time, (e.g. at a livestock 
market, a common pasture, a transportation, etc.). The probability of transmission 
will depend on whether the infectious animal is in contact with a pregnant recipient 
or not, as well as the duration of their infectious period (Lindberg A. and Houe H., 
2005).  
4.3. The role of biologicals  in BVDV transmission 
The biologicals (vaccines, cryopreserved embryos and semen) as vehicles for 
BVDV infection are potential to transmit the virus not only to neighbouring herds or 
between regions or countries, but also between continents (Stringfellow DA., et al., 
2005). As vaccines or semen from the same batch/bull will be used in many herds, 
the extent of such transmission can be vast and the consequences severe (Givens 
MD., et al., 2003).  
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Viral contamination of semen can result from four distinct types of infections 
with BVDV: a) PI bulls, b) acute infection of bulls due to exposure after development 
of immune-competence and c) prolonged testicular infection of bulls due to an 
enduring infection of testicular tissue after acute infection (Gard JA., 2007). 
PI bulls could shed large quantities of BVDV in semen (107.6 CCID
50
/mL) 
which can survive processing and cryopreservation. This contaminating virus will 
consistently infect susceptible, inseminated heifers and cows and occasionally may 
result in production of PI calves. Acutely infected bulls can shed BVDV in semen 
from 2 to 20 days after infection. The concentration of BVDV in these contaminated 
semen samples (5– 75 CCID
50
/mL) is much less than detected in semen of PI bulls 
(Gard JA., 2007; Rikula U., et al., 2008). Resulting acute infections can cause 
proliferation of BVDV within a herd which results in new PI developing foetuses, 
creating a temporal window for transmission of small quantities of virus on a limited 
basis to susceptible semen recipients. Thus, semen from PI or acute infected bulls 
creates a risk of viral transmission via artificial insemination, in vivo embryo 
production, and in vitro embryo production (Bielanski A., et al., 2008). 
In the same way, the presence of potentially live virus in foetal-calf sera is 
also suggested as probable way in which BVDV could be transmitted by embryo 
transfer. Such products are regularly used in the production of in vitro fertilised 
embryos and also for in vivo produced embryos. Embryo processing (i.e. washing or 
trypsin treatment) will certainly reduce the level of contamination should embryos be 
exposed to the virus (Lindberg A. and Houe H., 2005).  
In other hand, contamination of Modified Lived Vaccines (MLV) with 
adventitious viruses, particularly virulent BVDV, during the manufacturing process 
has represented a significant risk factor since these products were introduced in the 
world  marketing. The main source of adventitious BVDV is foetal bovine serum 
used as supplement in cell culture medium used in cell cultures to grow vaccine 
virus. Between 20% and 50% of commercial foetal bovine serum have been 
identified positive for both genotypes, predominating genotype 1 of BVDV (Houe H., 
1995). In recent years, confidence in purity of MLV BVDV vaccines has increased, 
as more attention has been focused on this issue and as improved test have been 
used as RT-PCR and others techniques. Foetal bovine serum that pass rigorous 
testing procedures and are shown to be negative for virus may be irradiated or 
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chemically treated as an additional precautionary measure before being used in cell 
culture production systems to grow vaccine virus (Kelling CL., 2004). 
 
4.4. The role of non bovine host  
Infected cattle is considered the most possible source of infection for other 
herds. If there are other sources of the infection that cannot readily be controlled by 
bio-security measures, the prospects for successful BVDV control could be 
hampered. In fact, the presence of non-bovine hosts of BVDV has been put forward 
as a reason why eradication could not be achieved in some situations (Houe H., 
1995).  
As suggested in previous reports, areas where wild ungulates and cattle 
breed and graze synchronically have theoretical precondition for transmission 
(Anderson EC.,  et al., 1998). However, in order for wildlife to act as a long-term 
reservoir, the virus needs to be able to infect cattle and persist in wildlife populations 
without being reintroduced (Vilcek S.,  et al., 2000). 
Pestiviruses are not strictly host-species specific and can infect not only 
domestic but also wild animals. Serological examinations provide evidence for the 
contact of free-living animals as cervidae, roe deer, red deer, fallow deer, mule deer, 
white-tailed deer and caribou. BVDV antibodies were also found in buffalo, giraffe, 
bighorn sheep, eland, chamois, pronghorn antelope, camelids and many other wild 
animals mostly from Africa and America. Different researches have shown that 
BVDV can replicate in species such as camels, deer, elk and bison. Natural infection 
has been described also in pigs, alpacas, sheep, goats, buffalo and wild deer 
(Nielsen SS., et al.,  2000; Frölich K., et al., 2006; Duncan C., et al., 2008). 
Currently and due to the prevalence of BVDV, it is difficult to measure or 
predict the importance of secondary hosts in the maintenance of the virus in cattle 
populations. As the prevalence of BVDV is reduced by prevention and control 
methods, it is likely that the significance of infections in secondary hosts will be 
comprehended (Brock KV., 2003). 
 
4.5. Risk  factors 
Epidemiological investigations have shown that demographic factors such as 
herd size and density are significant predictors for the prevalence of infection in 
populations where BVDV is endemic (Houe H.,1995; Valle PS.,et al., 1999). 
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Epidemiological data show that BVDV spreads more efficiently in areas with high 
cattle density. In such areas, where more herds will tend to be BVDV positive, the 
economical losses are often moderate and constant. Conversely, in areas whit low 
cattle density, more herds are likely to remain free from BVDV even without active 
control measures (Ezanno P., et al., 2008; Talafha AQ., et al., 2008). If BVDV is 
introduced to naive breeding herds, initial losses due to reproductive failure or 
clinical disease in calves infected in uterus may be substantial, but once adult 
animals have gained immunity to the virus, the continued BVD-related losses will be 
lower (Sandvik T., 2005).  A significant higher seroprevalence and  infection level 
have been observed in medium and large size herds than small herds.  As well, 
higher seroprevalences are observed in herds that purchase animals from different 
sources. Thus, important risk factors as herd size, exchange of visits between 
adjacent farm workers, absence of calving pens, contact with cattle from other herds 
such as pasturing at close distance, fence break out, animal shows and the lack of 
isolation of purchased animals, have an important influence on spread and  
transmission of BVDV (Lindberg A. and Houe H., 2005; Ezanno P., et al., 2008). 
 
5. PATHOGENESIS OF BVDV INFECTIONS  
5.1. Acute infections  
Acute infection of immunocompetent cattle with BVDV can result in a wide 
range of clinical syndromes. The majority of acute BVDV infections are caused by 
NCP viruses. PI and TI animals are the primary source of virus, shedding virus 
mainly in nasal and oral secretions (Kelling CL.,2004). The primary virus entrance is 
probably by oral and nasal routes. Following entry and after the contact with the 
mucosal lining of the mouth or nose, viral replication occurs in epithelial cells with a 
predilection for the palatine tonsils, lymphoid tissues, and epithelium of the 
oropharynx. Phagocytes take up BVDV or virus-infected cells for transport them to 
peripheral lymphoid tissues, but the virus is also able to spread systemically through 
the blood stream. Viremia is evident 2 to 4 days after exposure and virus isolation 
from serum or leucocytes is generally possible between 3 and 10 days post infection 
(Fray MD., et al., 1998; Brackenbury LS., et al., 2003).  During systemic spread, the 
virus is able to gain entry to most tissues with a preference for lymphoid tissues. 
However, the tissues infected may vary between different virus strains. Following 
acute infection, it is generally accepted that most clinical outcomes are mild as fever, 
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diarrhoea, and leucopoenia (Booker CW., et al., 2008). However, some CP strains 
have been associated with much more severe disease including fatal hemorrhagic 
diarrhoea and thrombocytopenia (Bezek DM., et al., 1994). Secondary infection by 
other pathogens may occur because of immunossupression. Finally, antibodies 
effectively neutralize viral infectivity, promote clearance of virus, and prevent 
seeding of target organs and foetus (Chase CC., et al., 2004; Smirnova NP., et al., 
2007). 
 
5.2. Intrauterine infections  
Throughout acute infections, infected cows could course a non-suppurative 
oophoritis with necrosis of granulosa cells, reducing the fertility rates consecutively 
(Grooms DL., 2004; Larson RL., 2004 and 2006). During pregnancy, BVDV has the 
ability  to cross the placenta and cause intrauterine infections. The outcome of these 
infections are largely dependent on the stage of gestation when infection occurs. 
Embryos appear to susceptible following implantation which occurs at day  20 of 
gestation. During this early phase of pregnancy, infection with BVDV often results in 
early embryonic death and resorption. Foetal infection during the first trimester of 
gestation can result in abortion and foetal mummification. If the foetus survives to 
this early infection, they invariably become PI and immunocompetent (Brock KV., 
2003; Brodersen BW., 2004).    
Foetal BVDV infection during the late first, second and early third trimester of 
gestation may also result in the formation of several different types of congenital 
anomalies. As the immune system develops during the second trimester of 
gestation, the foetus is able to mount an immune response to a BVDV infection, 
which results in the birth of clinically normal calves with BVDV pre-colostral 
antibodies (Browline J., 1998).  
 
5.3. Mucosal disease (MD) 
MD occurs only in cattle that had been infected with a NCP BVDV during the 
first trimester of gestation (PI animals) (Tautz N., et al., 1998), and occurs when 
these animals are superinfected by an antigenically homologous CP strain. Both 
viral biotypes, NCP and CP BVDV, are consistently found in animals that come 
down with MD (Kümmerer BM., et al., 2000; Bolin SR., et al., 2004). The super-
infection of the PI animal with an antigenically similar CP BVDV can occur in several 
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ways. The most common occurrence is for a mutation of specific sites in the NCP 
virus genome. This mutation may occur in several different ways including insertion 
of RNA into or deletion of RNA from the NCP BVDV genome. The mutation does not 
change the antigenic make-up of the virus, therefore the CP virus is not recognized 
by the host's immune system and is allowed to replicate without challenge. Other 
sources of CP viruses would include MLV or experimental challenge. Antigenic 
homology between the CP and NCP virus must be maintained for MD to occur. 
Replicating CP BVDV results in rapid depletion of the gut-associated lymphoid tissue 
(Peyer’ s patches) with subsequent necrosis of the gastrointestinal mucosa 
(Hamers C., et al., 2001).  
 
6. CLINICAL SIGNS   
There is some evidence that a particular type of BVDV correlates with a 
defined clinical-pathologic  presentation (Fig. 6). The practical significance of biotype 
is that, in vivo, NCP viruses may establish persistent infections but CP viruses do 
not. NCP viruses predominate in nature, meanwhile CP viruses are relatively rare 
and usually found in association with outbreaks of MD, a relatively infrequent but 
highly fatal form of BVDV infection (Houe H., 1995 and 2003; Lindberg A., et al., 
2005). Cytopathology in vitro does not correlate with virulence in vivo (Bezek DM., et 
al., 1994) and the most clinically severe form of acute BVDV infection is associated 
with NCP virus (Pellerin E., et al., 1994; Ridpath JF., et al.,1994). NCP BVDV-1 
strains are more correlated with respiratory disease than CP BVDV-2  genotypes 
(Baule C., et al., 2001). Clinically severe BVDV, also known as severe acute BVDV 
(SA-BVDV), occurs in animals infected with a type 2 BVDV that have no or low titers 
against BVDV2 strains. It is associated with a greater than 50% reduction in 
circulating lymphocytes and platelets and body temperatures exceeding 40.6°C. 
Severe acute BVD may progress to hemorrhagic syndrome in some cases 
(Stoffregen B., et al., 2000; Liebler-Tenorio EM. et al., 2003). 
 
6.1. Subclinical BVD Infections 
 Both NCP and CP-BVD biotypes are associated with subclinical BVD 
infections. Approximately 70-95% of the animals that become infected with the BVD 
virus do not develop signs of disease that are directly caused by the virus. However, 
subclinical infections may be accompanied by a decrease in meat or milk production 
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and a reduction in reproduction performances (Moerman A., et al., 1994; Dubovi EJ., 
1994). Generally, BVD subclinical infection causes a decrease in the animal's 
resistance to other secondary  infections.  These infections quite often are not 
recognized as being initiated by the BVD virus. For example, when the BVD virus 
infects the lungs of calves, the virus causes little or no disease. However, the virus 
interferes with the ability of the lungs to rid themselves of bacteria that are found 
routinely in the respiratory tract. The BVD virus has been identified as one of the 
most significant disease organisms involved with respiratory disease of cattle (Baule 
C., et al., 2001).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
        Fig. 6. Principal outcomes after  BVDV infection with differente genotypes and biotypes 
 
6.2. Peracute BVD Disease 
This disease syndrome is usually associated with the Type 2 NCP BVDV 
infection. The affected animals will exhibit high fever, occasional diarrhea, 
respiratory disease, and loss of appetite or anorexia. Peracute BVD can affect cattle 
of all ages and often results in the death of the animal within 48 hours from the onset 
of disease (Kelling CL., 2004). 
 
6.3. Acute BVD Disease 
The classic acute BVD form can be caused by either CP or NCP  strains, but 
are most common caused by NCP strains. The infection may result in a wide range 
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of clinical manifestations, varying from clinically unapparent to severe. BVDV 
replicates in monocytes, B cells, T cells, and epithelial cells of the gastrointestinal 
and upper respiratory tracts; and in this way the virus contributes to cause 
respiratory disease and enteritis (Baule C., et al., 2001). The infection  is 
characterized by high morbidity, low mortality, normal host immune response and 
minimal mucosal lesions. Signs as fever, discharge from the nose and eyes, 
erosions of the muzzle and in the mouth, severe and transient  hemorrhagic watery 
diarrhoea, rapid respiration, ptyalism, inappetance, coughing, depression, 
lymphopenia and trombocytopenia, petechial and ecchymotic hemorrhages, 
bleeding from injection sites, abortion and pneumonia could be observed (Odeon 
AC., et al., 2003; Kelling CL, 2004; Smith DR.,  et al., 2004; Dabak M., et al., 2007).   
The clinical picture can vary from animal to animal, especially as it relates to 
the presence of erosions and diarrhea. Diarrhea is usually present in every herd that 
has an outbreak of acute BVD, but diarrhea is not present in every animal that has 
acute BVD. In susceptible herds, clinical signs usually affect animals ranging from 6  
to 12 months old (Baker JC., 1995). The virus can be recovered from blood and 
nasal secretion of acutely infected cattle from 6 to 8 days, and antibodies titers rise 
slow for 3 months post-infection. The slow  increase of antibody titter may be due to 
the immunosuppressive effect of the virus (Peterhans E., et al., 2003). Acute BVDV 
infections play an important role as immunosuppresive agent or as potentiator of 
other diseases. Although the majority of acute infections are subclinical, acute 
infections are also occasionally identified as primary cause of mortality in calves. 
The profound immunosupresive effect of acute BVDV are responsible for the 
potentiation of a variety of diseases in cattle, including bacterium diseases like 
Salmonellosis, Escherichia coli, Mannheimia haemolytica, Mycoplasma bovis, 
Mycobacterium bovis, and viral infections as rotavirus, coronavirus, IBR, etc.  Acute 
BVD infections in the newborn calf may be more prevalent than is currently 
recognized because the disease is usually masked by secondary infections that 
cause diarrhea and/or pneumonia (Potgieter LN., 1995; Campbell J.R., 2004).  
 
6.4. Chronic BVD disease 
The chronic form of BVD is associated with prolonged BVD virus infections 
and very poor or absent antibody titer to the BVD virus. The clinical signs associated 
with the chronic disease are more sever than the clinical signs associated with the 
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acute BVD disease. The chronically diseased animals exhibit depression, a lack of 
appetite, a lingering diarrhea, a yellowish discharge from the eyes and nose, crusted 
muzzle, erosions of the mouth, bald spots due to loss of hair, and lameness due to 
inflammation of the hair line, sensitive laminae, and the tissue between the claws of 
the feet. The chronically infected animals usually appear unthrifty and starving. 
Death occurs more frequently in chronic BVD infections than in acute BVD infections 
(Odeon AC., et al., 2003; Liebler-Tenorio EM., et al., 2003).  
 
6.5 Reproductive signs  
BVDV can cause a wide array of reproductive losses that are largely 
dependent on the time of gestation when infection occurs (Fig. 7). 
 
o Infection from 0 to 45 days of gestation. BVDV reduce significantly the 
conception and pregnancy rates in infected animals, maybe because it is 
associated with the failure of fertilization or early embryonic death (EED). 
Several studies have shown that following an acute infection with CP BVDV, 
the animals develop an interstitial oophoritis with lesions lasting up to 60 days. 
Other features as infection and subsequent viremia during preovulatory phase, 
hypoplastic ovaries, infertility, salpingitis for up to 21 days and the decrease of 
viability of blastocyst have been described (Smith DR., et al., 2004; Grooms 
DL., 2004). 
o Infection from 45 to 175 days of gestation. Following implantation, 
transplacental infection of the developing foetus can occur in susceptible cows 
with either biotype of BVDV. The outcome of the infection is largely dependent 
on the timing of the infection: 
a) Abortion. Under experimental conditions, both CP and NCP BVDV viruses 
can cause foetal death following infection of seronegative dams. This can occur at 
any point during gestation, although it is most common during the first trimester. 
Foetal resorption, mummification or expulsion can also occur  depending on the time 
of infection (Swasdipan S., et al., 2002; Greiser-Wilke I., et al., 2003). 
b) Immunotolerance.  Non-lytic infections produced by NCP BVDV strains and 
the ability to evade the host immune response are the primary mechanisms of 
persistence (Brock KV., 2003). Foetus that survive infection with NCP BVDV 
between 18 and 125 days of gestation invariably develop immunotolerance to the 
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virus and subsequently become PI with BVDV. This mechanism is due because the 
virus proteins are recognized as self-antigens, resulting in a negative selection of 
BVDV specific B and T lymphocytes. NCP BVDV is the only biotype that has been 
able to natural and experimentally produce persistence (Greiser-Wilke I., et al., 
2003; Ridpath JF., 2003 and 2006a). 
c) Congenital defects. Foetal infection between 100 and 150 days of 
gestation, often results in the development of a variety of congenital defects. During 
this stage of gestation, organogenesis is being completed and the immune system is 
becoming fully functional. The NCP biotype can replicate in the early foetus, causing 
damage to selected tissues but not sufficient to cause death. Congenital anomalies 
as hypomyelination of the central nervous system, microencephalopathy, 
hydrocephalus, hydranencephaly, porencephaly and cerebellar hypoplasia are 
observed. The cerebellar hypoplasia is the most common and the calves born with 
this disorder show tremors, ataxia, wide-based stance and stumbling gait. Other 
teratogenic effects associated to BVDV are cataracts, microopthalmia, retinal 
degeneration, optic neuritis, hypotrichosis, alopecia, mandibular brachygnathism and 
growth retardation (Riond JL., et al., 1990; Grooms DL., 2004; Smith DR., et al., 
2004).       
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Fig. 7. Potential clinical reproductive outcomes following infection with BVDV. EED: early embryonic 
dead (Grooms DL., 2004). 
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o Infection from 125 to 285 days of gestation. In the later stage of gestation, 
immunocompetence and organogenesis are usually complete. Although 
abortions and the birth of weak calves have been attributed to infection with 
BVDV late in gestation, foetuses infected during this time period are normally 
able to mount an affective immune response and effectively clear the virus, 
having pre-colostral neutralizing antibodies to BVDV. Even that, some abortions 
and weak calves have been reported from BVDV infection during this period 
(Wittum TE., et al., 2001; Smith DR., et al., 2004).  
 
6.6.  PI animals 
Calves PI are persistently viremic and shed the virus continuously (Houe H., 
1999; Kuhne S., et al.,  2005). PI calves may appear normal, but are frequently poor-
doers having reduced growth rates, immunosuppression, increased morbidity and 
mortality because they are more susceptible to many calfhood disease, such as 
pneumonia. PI animals may also develop MD, usually before they are 2 years old 
(Odeon AC., et al., 2003). Erosions of the nose, muzzle and interdigital cleft and 
crustaceous dermatitis occasionally described in persistently BVDV-infected cattle 
and corroborate the potential of BVDV for tissue damage in such locations (Dabak 
M.,  et al., 2007).  
 
6.7. Mucosal Disease (MD) 
MD is a sporadic disease in cattle that often occurs between the ages of  6 
months and 2 years. The disease is characterised by high case fatality with death 
occurring usually within 2 weeks after the onset of clinical signs (Baker JC., 1987). 
Extensive ulceration of the gastrointestinal tract is the most prominent lesion. 
Characteristic clinical signs of mucosal disease include anorexia, fever, diarrhea, 
dehydration, presence of lesions in the mucous of the digestive tract, necrosis of 
lymphoid tissue, hoof inflammation, and loss of condition and death (Wilhelmsen 
CL., et al., 1991;Kelling CL., 2004). Dermatitis is a sign frequently present in MD and 
is the common finding of the BVDV in skin biopsy specimens in PI cattle, confirming 
the tropism of the virus for the epithelia (Wilhelmsen CL., et al., 1991;Dabak M., et 
al., 2007).  
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7. IMMUNE RESPONSE 
7.1. Innate response 
        INTERFERON. Interferon is the most important innate defence antiviral 
cytokine. Viral infections commonly result in the induction, release, and remote 
action of type I IFN’ s, notably IFN-α, IFN-γ, as well as the newly described IFN-τ 
(Brackenbury LS., et al., 2003). Released IFN acts through specific receptors 
present on nucleated cells to transduce signals for the transcription of numerous 
genes, such as the genes encoding the double-stranded RNA (dsRNA)-dependent 
protein kinase (PKR), the 2’ -5’ -oligoadenylate synthetase (2’ -5’ -OAS). PKR 
and 2’ -5’ -OAS are produced as inactive precursor molecules. Once activated by 
viral dsRNA intermediates, these effectors act to inhibit the host’ s cell transcription 
machinery and ultimately contribute to the induction of apoptosis of virus-infected 
cells. However, NCP virus inhibits double-stranded RNA that induces apoptosis and 
the interferon synthesis. This phenomena is associated with the establishment of 
persistence in the bovine fetus (Peterhans E., et a.l, 2003; Chase CC., et al, 2004). 
 
APOPTOSIS. This mechanisms may be triggered hours to days before the 
onset of the virus specific immune response highlights and it is considered as a one 
of the first line of defense. It is no surprise, that BVDV has evolved mechanisms that 
prevent apoptosis and subvert the IFN response. NCP biotypes of BVDV do not 
induce the synthesis of IFN’ s, and cells show no signs of viral infection. Some 
studies show that  NCP BVDV inhibits apoptosis, IFN mRNA and protein synthesis 
induced by poly(IC), a synthetic form of dsRNA (Schweizer M., et al, 2006). By 
contrast, CP BVDV induce the synthesis of IFN type I and by intrinsic pathway and 
oxidative stress related mechanisms, activates the kinase cascade, acting as 
important trigger for apoptosis. At the same time, CP BVDV enhance the production 
of TNF-α which is an inductor factor of apoptosis (Yamane D., et al., 2005).  
 
 ANTIGEN PRESENTATION CELLS (APC).  APC are pivotal for the induction 
and control of BVDV immune responses. These cells internalize antigen and present 
BVDV peptides to T lymphocytes CD4+ (TL helper cells) using the peptide binding 
site associated with major histocompatibility II molecules (MHC II). In addition, 
cytokines such as IFN-γ and interleukin 12 (IL-12) and other co-receptor molecules 
such as B7 are required for adequate presentation and stimulation of T helpers cells.  
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Even this response, the BVD virus has the ability to cause  a reduction of Fc and C3 
receptor expression in APC and both, CP and NCP strains, downregulate the MHC II 
expression in a 30 to 50% (Brackenbury LS., et al., 2003; Glew EJ., et al., 2003).  
 
EMBRYO RESPONSE TO BVDV INFECTION. The bovine trophoblast has 
been found to resist infection with BVDV for up to 30-40 days of gestation (Brownlie 
J., et al.,1998; Grooms DL, 2004). This phenomenon is possibly linked to the 
reported antiviral effect of IFN-τ, a constitutively expressed cytokine of the ruminant 
trophoblast  and its main function is believed to be in the maintenance of the 
gestation by preventing luteolysis in the ovary of the cow. IFN-τ is not induced by 
virus and is instead produced constitutively by the embryonic trophectoderm during 
the period immediately prior to implantation. This type of IFN is produced in very 
high concentration and has antiviral activity similar to the other type I IFNs, and it 
may well act to prevent infection of the embryo (Brackenbury LS., et al., 2003; 
Chase CC., et al, 2004).  
 
7.2. Adaptative Immune Response 
CELLULAR RESPONSE.  Lymphocyte T (TL) CD4+ cells play a pivotal role in 
coordinating a cell-mediated response early in the infection. These CD4+ responses 
are directed primarily to the BVDV proteins NS3 and E2 and also against the capsid 
protein (C), glycoprotein Erns, amino-terminal proteinasa (Npro) and nonstructural 
protein 2-3 (NS2-3) (Pankraz A., et al., 2005). The proliferative T response occurs 
faster with CP than NCP infections, but the CP infections produces approximately 
twofold higher cell-mediated response (Th1) than NCP. In contrast, NCP BVDV tend 
to shift the immune response toward the Th2 response and avoid the production of 
high levels of cell-mediated immunity resulting in a high production levels of 
antibodies  (Chase CC., et al, 2004; Lee SR., et al., 2009). This fact can explain why 
the antibody level in NCP BVDV infected dams rises throughout pregnancy and  
rapidly declines following calving and abortion. The level of antibody in these dams 
is extremely high by 180 days of pregnancy and it was observed that in dams 
carrying PI foetuses, the immune response was markedly higher than in those dams 
carrying uninfected foetuses (Collen T., et al., 2000; Smirnova NP., et al., 2008). 
TL CD8+ cytotoxic play a role in the immune response to acute BVDV 
infections, producing high levels of IL-2 and IFN-α, indicating a type one memory 
 26 
response in seropositive cattle. The presence of BVDV has been demonstrated after 
9 months post- infection. The expression of MHC class I molecules on infected  cells 
affects the CTL response. In vitro, NCP BVDV causes a 30-40% reduction in MHC 
class I expression, meanwhile CP BVD virus increase its expression (Collen T., et 
al., 2002). 
 
HUMORAL RESPONSE. The principal antigenic structural polypeptides are 
the capsid (C), and the glycoprotein glycosylated Erns that although shows to 
produce significant levels of antibodies, has limited neutralizing activity. Glycoprotein 
E2 is the major antigen target for antibodies (Chimeno Z.S., et al., 2007). E2 is high 
antigenic and elicits the production of neutralizing antibodies in the host after the 
vaccination with live or killed vaccines. BVDV type 1 E2 protein has one 
immunodominant epitope, while BVDV 2 has three.  In the case of non structural 
protein 2-3 (NS23), naturally infected or cattle vaccinated with MLV develop a strong 
antibody response to this protein, while cattle vaccinated with inactivated vaccines 
develop little NS23 antibody (Fulton RW., et al., 2003).  
7.3. Immunosuppression 
The changes related to the immunosuppressive action of BVDV include, 
among others, decreased lymphocyte proliferation and affecting the function of 
neutrophils, monocytes, macrophages and dendritic cells. In vitro, BVDV-infected 
monocytes become apoptotic when infected by CP BVDV, and produce soluble 
factors that induce apoptosis in uninfected monocytes, lympocytes and epithelial 
cells. This ability  may be part of the pathology in lymphoid tissue associated with 
MD. The field infection with BVDV can results in a 30% to 70% of decrease in the 
monocyte numbers. BVDV infections have their major effect on thymic and follicular 
TL. The effect on the number of circulating TL in BVDV infections varies from a mild 
(10-20%) to severe lymphopenia (50-60%) with highly virulent NCP. BVDV infections 
causes depletion of both CD4+ and CD8+ TL in the thymus, and there is an overall 
reduction in TL in the spleen (Piccinini R., et al, 2006; Brewoo JN., et al., 2007; 
Shoemaker ML., et al., 2008). The different steps of the innate and acquired 
immunity affected by both CP and NCP BVDV biotypes are presented in the Tables 
1 and 2. 
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    Table 1. Effects of BVDV on the innate immune system (Chase CC., et al., 2004) 
 
Cellular and / or cytokine changes    Effect on the immune system 
Effect on the animal’ s 
disease response 
↓ Chemotaxis ↓  Neutrophil migration ↑ Microbial infections 
↓ Fc, CD14 and complement 
receptor expression 
↓ Phagocytosis ↑ Microbial infections 
↓ Phagocytosis ↓  Ingestion of MO ↑ Microbial infections 
↓ TNF-α 
↓ Inflammatory cytokine 
production 
↓ Innate and adaptive 
immune response 
↑IL-1 inhibitors ↓Inflammatory and T cell 
cytokine production 
↓ Innate and adaptive 
immune response 
↓ Superoxide production ↑ Microbial growth ↑ Microbial infections 
↓ Microbicidal activity ↑ Microbial growth ↑ Microbial infections 
↓ IFN production- NCP BVDV ↓ Antiviral response 
Immune evasion and viral 
infection 
↑ IFN production- CP BVDV ↑Antiviral response Apoptosis and death of the 
infected cells 
↑: increased, ↓ : decreased, CD14: LPS receptor, Fc: Immunoglobulin Constant Region Fragment, MO: 
microorganisms.    
 
 
8. PATHOLOGICAL FOUNDS 
8.1. Macroscopical  founds 
The pathological founds are confined in several systems. The main clinical and 
pathological findings associated with the clinical cases of NCP BVDV genotype 2 
include widespread mucosal congestion, deep and extensive ulcerations in dorsal 
and lateral epithelia of the tongue, gums and hard palate.  Congestion, multiple 
haemorrhages and small erosions could be distributed along the mucosa of the 
oesophagus, pillars of the dorsal sack of the rumen, mucosa of the abomasum and 
small intestine. Multiple white-yellowish spots diffusely distributed on the omasal 
mucosa and disseminated areas of congestion and ulcerations covered with fibrin in 
the small intestine could be observed. Pasty dark red hemorrhagic fluid filling the 
abomasums, small intestine, and caecum can be found, and the cut surface of the 
wall of the organs could appeare oedematous. It is common the presence of blood 
clots of several diameter attached to the mucosa of the ileum, some of them 
anatomically associated with the Peyer’ s patches. In general, the mesenteric 
lymph nodes are large, oedematous and hemorrhagic (Campbell JR., 2004; Liebler-
Tenorio EM., et al., 2006; Lunardi M., et al., 2008). 
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Interstitial emphysema, pneumonia and fibrinous pleural adherences are 
commonly found in the respiratory tract. Petechial haemorrhages can be present in 
epicardium and myocardium. In lymphatic system, several lymph nodes as pre-
scapular, scapular, popliteal and mesenteric are hyperplasic. In aborted foetuses, 
the principal lesions observed include conjunctivitis, pneumonia peribroncheal and 
non-specific myocarditis. Placental lesions consist mainly in vasculitis, oedema, 
congestion and haemorrhage with some degeneration and necrosis. Pathological 
founds in MD are similar than those observed in clinical cases but  with severe 
presentation. Gross examination can reveal digestive tract erosions and ulcerations, 
often covered with necrotic plaques, including the hard palate, dental pad, tongue, 
oesophagus and in most of the cases, all digestive tract is involved (Liebler-Tenorio 
EM., et al., 2003 and 2006). 
  
   Table 2. Effects of BVDV on the adaptive immune system (Chase CC., et al., 2004). 
Cellular and / or cytokine changes Effect on the immune system 
Effect on the animal’ s 
disease response 
↓  MHC II expression ↓  Antigen presentation ↓ Adaptive immune response 
↓  MHC I expression- NCP ↓   CTL-killing 
↑ Immune evasion and viral 
infection 
↑ T helper 1 activation- CP ↑ CTL response, T cell memory ↑ Long term protective 
response 
↑T helper 2 activation- NCP ↑ B cell activation ↑ Ab production, ↓  CMI 
response 
↑: increased, ↓ : decreased, Ab: antibody, CMI: Cell Mediated Response, CTL: cytotoxic T-lymphocyte, MHC: 
Major histocompatibility complex. 
 
8.2. Histophatological  founds 
The principal microscopic lesions observed  in highly virulent NCP BVDV 
infections reveal severe Lymphocyte T and B depletion and haemorrhages in 
peripheral and general lymph nodes, meanwhile depletion of lymphoid follicles of 
Peyer’ s patches occurs with both MD and highly virulent NCP BVDV infections. 
Thymus presents lymphoid depletion in the cortex, and in the tonsils is commune to 
find follicular hyperplasia and degeneration of germinal centers and necrosis (Odeon 
AC., et al., 2003; Chase CC. et al., 2004).  
In the digestive tract, lymphocyte infiltration, lymphoid depletion and mitosis 
are the principal lesions. The mesenteric lymph nodes could present hyperplasia of 
germinal centers, necrosis, lymphoid depletion with mitosis, and eosinophil 
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granulocyte infiltration. Individual cell necrosis and vacuolation are present in the 
basal stratum and spinosum stratum of the squamous epithelia of the tongue and 
oesophagus, and associated with these changes, mononuclear cell reaction 
(macrophages and lymphocytes) and bacteria colonies could be present. The 
epithelia of rumen could present cell necrosis and a mild non-suppurative 
inflammatory reaction. Intestinal lamina propria of the small intestine can have 
several haemorrhages and moderate inflammatory reaction composed by 
macrophages, lymphocytes and plasma cells. Also, epithelial degeneration and 
necrosis are the prominent findings in the small intestine. The affected crypts can be 
dilated and contained large amounts of cell debris with mixed neutrophils and 
macrophages (Liebler-Tenorio EM., et al., 2003 and 2006).  
 In respiratory tract, an acute catarrhal inflammation in nasal cavity and 
trachea can be observed. The lungs could present moderate congestion and 
lymphocytic interstitial reaction. Moreover, areas of emphysema with haemorrhages 
and fibrin clots within emphysematous alveoli, peribronchial lymphoid hyperplasia, 
focal intralobular interstitial pneumonia, bronchiolitis and focal atelectasis can be 
observed. The liver could presents focal-subacute inflammations and the kidneys 
can show a focal interstitial inflammation and proliferation of mesangium cells in the 
glomeruli. The brain presents perivascular lymphohistiocytic inflammation and 
panencephalitis. The spleen can show infiltration with neutrophil granulocytes in the 
red pulp, hyperplasia of Malpighian bodies, necrosis, mitosis and lymphoid depletion 
(Baule C., et al., 2001). 
In aborted foetus, the principal pathological founds are thymus hypoplasia  
implicated with a morphological immaturity and necrosis and depletion of 
lymphocytes, attended by infiltration of macrophages. Histopathological changes are 
also noted in the cerebellum consisting of necrosis and depletion of the external 
germ layer (Swasdipan S., et al., 2002). 
 
9. DIAGNOSIS 
Although BVDV infection can be suspected from clinical signs, the wide range  
in both diversity and severity makes them the best unreliable for diagnostic 
investigations. Laboratory tests are mandatory, and should furthermore be used  in a 
planned way to give useful information.  In the current BVDV programmes, the aim 
of the organized diagnostic work is to identify and remove the animals that are the 
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sources of infection. To achieve this, identification of several categories of animals is 
necessary (Table 3). 
9.1. Antigen  detection   
      Virus isolation (VI) 
Culture and identification of BVDV from clinical specimens remains the “ gold 
standard” diagnostic technique (Sandvik T., 2005). Since BVDV appears to 
replicate best in lymphoid cells, samples than contain this cell types should be 
considered. The samples would include whole blood, buffy coat, lymphoid tissues  
such as Peyer’ s patches, mesenteric lymph nodes, spleen and thymus from post-
mortem cattle or aborted foetuses, meanwhile from PI animals, virus can be isolated 
from blood, serum, buffy coat and a majority of tissues.   
BVDV readily grows in many cells lines, however, only three are most widely 
used in the laboratories for BVDV isolation: bovine turbinate (BT), bovine testicle 
(Btest) and Madin Darby Bovine Kidney (MDBK) (Sandvik T, 2005; Cornish TE., et 
al., 2005). Foetal calf serum used to supplement the cell culture medium should be 
free from both BVDV and BVDV-specific antibodies. An incubation period of 4 to 5 
days is sufficient for BVDV isolation. However, about  1 in 25 positive BVDV 
isolations require a second passage. For detection of NCP BVDV in blood from PI 
animals, cells cultured in 96-well microtitre plates and inoculated with 10-50 µl serum 
for 4 days may give satisfactory results (Sandvik T., 1995). The growth of BVDV 
may or may not cause any visible cytophatic effects and most of BVDV isolates (70-
90%) are of the NCP biotype. This means that upon completion of virus isolation, 
cells cultures need to be further tested to detect the presence of NCP BVDV. This is 
generally performed by fluorescent antibody (FA) staining and Immunoperoxidase 
(IP) test (Saliki JT., et al., 2004; Hilbe M., et al., 2007).  
For these techniques, the inoculated cells are routinely fixed after 3-5 days. 
The standard IP assay has proven to be an useful compromise for detection of PI 
animals in serum, where the virus may be present in concentrations 102– 103 higher 
than in acutely infected animals (Muñoz-Zanzi CA., et al., 2000). Primary antibodies 
for the immunostaining can be raised locally, or obtained commercially (panpesti-
virus reactive monoclonal antibodies are also suitable). For a given cell line, the 
sensitivity to infection may decline when it reaches a given passage number. If foetal 
calf serum is used as medium supplement, it must be free from antibodies to BVDV 
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as well as the virus itself, otherwise the sensitivity of the IP is compromised. Virus 
isolation is an essential back-up and reference test for other indirect methods used 
for identification of PI animals. Unfortunately, VI methods are labour intensive and 
take several days to be completed, and may not differentiate between TI and PI 
animals, unless positive cattle are re-tested and remain positive at a later date of 3 
weeks (Cornish TE., et al., 2005; Edmondson MA., et al., 2007). 
 
Table 3. Categories of animals in an unvaccinated bovine population where BVDV is prevalent, and 
usual results of testing for antibodies and virus in serum 
CATEGORY ANTIBODY VIRUS COMMENTS 
Uninfected, naive animal - -  
Acutely infected animal - +/- Brief and low virus titre in blood 
Immune animal after acute 
infection 
+ -  
Passively immunized calves + - 
Antibodies detectable for 5-9 
months 
PI animals - +  
PI calves of immune dams + -/+ 
Antibodies detectable for 4-10 
weeks 
Mucosal disease cases -/+ +/- Neutralizing antibodies 
Pregnant cow carrying PI calf +/++ - 
High antibody titre in late 
pregnancy 
Immune bulls + - Semen may be virus positive 
                                                                                                                                                               Sandvik T, et al.,  1999 
 
Antigen Capture Enzymelinked Immunosorbent  Assay (ACE-ELISA)  
To identify PI animals, VI on primary bovine cells, followed by IP staining is 
regarded as the "gold standard" method (Saliki JT., et al., 2004). Even the IP test 
has shown to be highly effective for identifying PI animals, the test is time consuming 
and requires a high investment both in personal training and laboratory equipment. 
For that reason,  ACEs  have been increasingly  used since the early 1990's. 
 The NS2/3-capture ELISA detects BVDV in leukocytes and tissue samples 
using specific affinity monoclonal antibodies (MAb) against the NS2/3 protein, and 
has been successfully used  to identify PI animals in BVDV control programmes in 
Norway and in the Shetland islands (Kampa J., et al., 2007). Recently, an ACE 
ELISA that uses MAbs against the Erns glycoprotein has been developed to detect 
BVDV. This structural protein is secreted from infected cells during virus replication 
 32 
and can be detected directly in blood, buffy coat cells, plasma, sera, ear notches or 
tissue extracts, producing reliable results (Kuhne S., et al., 2005; Kennedy JA., et 
al., 2006; Hill FI., et al., 2007). Even this results, the necessity to extract buffy coat 
cells or process tissue before testing, somewhat limits the applicability to these tests 
on a large number of samples as requires in whole-herd screening PI animals. In the 
same way, one of the major complicating factors for viral antigen detection in serum 
or peripheral blood leukocytes (PBL) is the presence of circulating antibodies 
(Brodersen BW., 2004), and It is generally accepted  that attempts at detection of PI 
animals less than 3 months of age should not be done due to the presence of 
colostral antibodies (Cornish TE., et al., 2005).  
A commercial kit to  detect BVDV antigen in samples as serum and plasma 
from PI cattle  has been used demonstrating  good results compared with VI and 
IHC (Saliki JT., et al., 2000; Plavsic MZ., et al., 2001). Lately, Erns ACE ELISA has 
been used as an alternative test due to its high sensitivity and specificity and its use 
in a precolostral screening (Kampa J., et al., 2007). Both samples, serum and skin 
samples tested with ACE resulted in the correct detection of all cattle identified as 
PI. Agreement between both ELISAs, performed on serum or skin together with PCR 
has been  reported of  100% (Hill FI., et al., 2007). About ear notches samples, it  
was reported a sensitivity of 100% and specificity of 99.6% using the commercially 
available kit on ear tagging obtained from PI animals. The ACE performed on skin 
provided the greatest ability compared with other diagnostic tests as VI, IHC and RT-
PCR to accurately identify animals that were both infected with BVDV (Positive 
Predictive Value of  100%) and animals truly negative for BVDV (Negative Predictive 
Value of 100%) (Kennedy JA., et al., 2006a and b; Edmonson MA., et al., 2007). 
Ear-notch samples are easy to collect, and preliminary studies have shown that fresh 
samples are stable, with no reduction in virus detection via ACE and RT-PCR in 
temperatures of – 20°C, 4°C, and 25°C for 7 days (Ridpath JF., 2003).  
In other hand, some researches have reported differences between the 
results obtained using sera and ear notches samples. Both samples from PI calves 
were tested using ACE,  and while sera samples were negative after intake of 
colostrum, the ear tissue samples could be detected positive for BVDV all the time. 
In the same way, testing multiple samples derived from the same ear from PI cattle 
yielded positive results with low  variation (Kuhne S., et al., 2005).  
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Two techniques performed on ear notches, IHC and ACE were compared for 
detection of BVDV PI animals. Both IHC and ACE detected 100% of PI calves, 
however, both techniques also detected  acutely infected calves, recommending to 
repeat the test using VI or RT-PCR on buffy coat samples 30 days after initial 
screening to conclusively discriminate between acute and PI animals (Cornish TE., 
et al., 2005). Saliki and Dubovi (2004), suggested that acutely infected animals will 
not have a significant amount of antigen in the skin tissue in the vast majority of 
cases and that skin samples should be obtained for PI status determination, thus 
they further suggested that ACE could be  primarily useful in screening for PI cattle. 
 
 Immunohistochemistry (IHC) 
In recent years, BVDV antigen detection in formalin-fixed paraffin-embedded 
tissues by IHC staining has been widely used for diagnosis of acute infections as 
well as to detect PI animals (Liebler-Tenorio EM., et al., 20004; Loneragan GH., et 
al., 2005; Hilbe M., et al., 2007).  IHC can be applied on snap-frozen or formalin-
fixed paraffin embedded skin biopsies or a wide range of tissues, such as thyroid 
gland, bone, brain, and mucosal membranes. The distribution of viral antigen in the 
skin of PI animals has shown to be generalized, but principally is found in aural, 
neck, brisket, coronary band and tail head skin (Brodersen BW., 2004). Positive IHC 
staining was shown to be more pronounced in the keratinocytes and in hair follicle 
epithelium, hair matrix cells of the hair bulb, and the dermal papilla. Generally, IHC 
staining uses the 15C5 monoclonal antibody, which reacts with the Erns protein of 
BVDV. These tests exhibit high levels of sensitivity and specificity that are 
considered adequate for use in screening programs aimed at detecting BVDV 
infections (Njaa BL., et al., 2000).  
 After the first report by using skin biopsies as method of detection of PI cattle 
in 1996, where the agreement of IHC and VI in positive and negative animals was of 
100% (Thur B., et al., 1996), other studies have shown similar results (Njaa BL., et 
al., 2000; Grooms DL., et al., 2002). In a study comparing IHC with VI and 
immunofluorescence (IF) for detection of BVDV in aborted and neonatal calves, the 
sensitivity and specificity of IHC, IV and IF were 97% and 97%,  83 and 100% and 
77% and 88% respectively (Ellis JA., et al., 1995). Another study demonstrated IHC 
testing of formalin-fixed paraffin-embedded tissues had 100% agreement with VI in 
cases of enteric and respiratory disease and abortion/weak calf syndrome 
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(Brodersen BW., 2004). Using IHC as the relative gold standard, the serum ACE 
ELISA  had a sensitivity and specificity of 100%, and the real-time RTPCR had a 
sensitivity of 100% and a specificity of 99% (Hilbe M., et al., 2007). 
In other hand, when an animal is acutely infected with BVDV or vaccinated with 
MLV BVDV vaccine, the likelihood of detection of viral antigen in a skin biopsy by 
IHC is low. This have been demonstrated in several studies where some calves 
were inoculated with BVDV, being all negative using skin biopsies. Animals 
experimentally infected with a large inoculum of virulent BVDV can have the antigen 
in their skin beginning between 8 and 14 days after inoculation, but the duration of 
which BVDV antigen may be present in the skin of TI cattle is not  well characterized 
(Brodersen BW., 2004). There are some evidences about the different antigen 
distribution between TI and PI animals, being confined to the epidermal 
keratinocytes and follicular ostia than in all layers of epidermis, all levels of hair 
follicles and hair bulb respectively (Shin T., et al., 2001). Brodersen BW. et al., 
(2004) also affirmed that skin samples from TI cattle are rarely positive by IHC.  
Some of the advantages of this test for detection of PI cattle are the easy 
sample collection and transport to the laboratory, the reduced costs for ear notch 
collection, and the stability of the samples comparing with serum or whole blood. 
Anyway, it is recommended that specimens are transported to the laboratory in a 
timely manner for improve the results.  
 
 Nucleic acid detection   
During the past 10 years, the Reverse Transcriptase-Polymerase Chain 
Reaction (RT-PCR)  has gained widespread use as a routine diagnostic method for 
BVDV (Smith RL., et al., 2008). The RT-PCR test, a relatively new diagnostic tool for 
demonstrating the presence of BVDV antigen has been used to detect infected and 
PI animals with BVDV, and theoretically, every imaginable animal specimen like 
milk, urine, tissue, serum, whole blood, buffy coat cells, swabs, skin, formalin-fixed 
tissues, etc., can be used (Drew TW., et al., 1999; Young NJ., et al., 2006). Lately, 
the use of oral swabs samples has been described as a useful method for screening 
and detection of  BVDV PI cattle by RT-PCR (Tajima M., et al., 2008). 
Detection of Pestivirus RNA by RT-PCR includes four different steps: 
extraction of RNA, reverse transcription to cDNA, primer-directed amplification and 
lastly detection of amplified products. Lately, with the new Real-Time PCR in a 
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single tube, the need of gel electrophoresis and the risk for carry-over contamination 
with previously amplified DNA are eliminated (Young NJ., et al., 2006). When 
complete genomic sequences of viruses from the Pestivirus genus are compared, 
the highest level of conservation is observed in the 5’ UTR, and for that reason, RT-
PCR assays using primers specific for this region have offered the best 
epidemiological sensitivity. At the same time, sequences variations in this region are 
conserved among viruses within the same Pestiviral  genotype, permitting their 
differentiation (Letellier C., et al., 1999; Vilcek S., et al., 1998).   
Cornish TE., et al. (2005) reported a complete agreement among IHC and 
ACE from skin samples, VI from white blood cells (WBC) lysates, and RT-PCR from 
WBC lysates from PI calves with BVDV. In the same way, using IHC as the relative 
gold standard, the RT-PCR has shown a sensitivity and specificity of 100% and 99% 
respectively (Hilbe M., et al., 2007). Additionally, RT-PCR test is a reliable way of 
diagnosing PI calves at all ages and it has been demonstrated that RT-PCR  is able 
to detect BVDV even in the presence of colostral antibodies (Letellier C., et al., 
1999; Luzzago C., et al. 2001; Saliki JT., et al., 2004; Sandvik T., 2005). Another 
useful diagnostic application of the RT-PCR method is monitoring of cell cultures 
and foetal calf serum used as cell culture medium supplement, both of which may be 
contaminated with NCP BVDV (Bolin  SR., et al., 1991).  
More recently, Real-Time PCR is being used to identify, classify and quantify 
many viral pathogens as it is a highly sensitive and rapid method for detecting viral 
nucleic acid sequences in clinical specimens. Real-time RT-PCR methods for 
genotyping BVDV have been described previously, using separate sets of primers 
and probes in the same assay (Lettellier and Kerkhofs, 2003). Real-time PCR offers 
the same advantages as conventional PCR assays, but is considered as a faster 
method due to real-time visualization of results (Baxi M., et al., 2006). When Real 
Time RT-PCR assay was compared with virus isolation in sera samples from PI 
animals, there was full agreement between both tests. Thus, the one-step Real-Time 
RT-PCR assay appears to be a rapid, sensitive, and specific test for detection and 
typing of BVDV (Baxi M., et al., 2006). In an other study, The TaqMan® RT-PCR 
assay was 10 times more sensitive than a gel-based RT-PCR, distinguishing three 
positive samples in heparin-treated whole blood that conventional RT-PCR failed to 
detect (Drew TW., et al., 1999). 
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RT-PCR and Real-Time PCR have become a sensitive and specific 
diagnostic methods for testing pooled samples as serum, milk, blood and 
supernatant from skin biopsy samples, and they have been evaluated as a low-cost 
alternative for diagnosis screening and surveillance of persistent infections (Kennedy 
JA., et al., 2006 a and b; Muň oz-Zanzi C.,et al., 2006). When determining the size 
of the pool, the pooling protocol should use the fewest number of tests required to 
identify all animals PI with BVDV in a herd. A simulation model for determining the 
economically optimum sample size in populations with various prevalences of PI 
found that the economically optimum sample size is dependent upon the prevalence 
of true positives in the population. For a PI prevalence of 0.5% to 1.0%, the optimum 
number of samples in an initial pool is 20 to 30, and as prevalence increases the 
least-cost initial pool size decreases. If the pool size is too large, there is an 
increased risk that any single pool will test positive, requiring additional testing to 
identify the small number of viremic animals in the positive pool. If the samples are 
grouped in unnecessarily small pools, the cost benefit of pooling samples is lost to 
the large number of negative pools tested for each positive pool identified 
(Weinstock D., et al., 2001; Larson LR., et al., 2005, Muň oz-Zanzi C.,et al., 2006).  
For an average prevalence of PI animals with BVDV of 0.01 and viremia in 
each animal between 102 and 107 virus particles/ml, the pool size associated with 
the lowest number of tests and cost corresponds to eight samples/pool (Muň oz-
Zanzi C.,et al., 2006). The use of RT-PCR on pooled ear-notch supernatant could 
provide an initial, rapid, cost-effective method of screening cattle herds for BVDV PI 
animals. Subsequent serial testing with an ACE to evaluate individual samples 
included in the positive pool could minimize the length of time other animals are 
exposed to the virus. Using this procedure, a sensitivity and specificity of 100% and 
97.5% respectively has been reported (Kennedy JA., et al., 2006 a and b).  
 
9.2 Antibody detection 
Studies aimed on immune response against BVDV have been concentrated 
on the demonstration of the presence of antibodies against the virus, which can be 
detected in serum from 3 weeks, and thereafter for years after acute infection in 
immunocompetent animals. Antibodies to viral glycoproteins (primarily E2) may 
neutralize the virus and can cross react with other strains of BVDV, but if sera raised 
against one virus strain are tested against other challenge viruses, different 
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antibodies titres may be obtained. Conversely, the highly immunogenic non 
structural viral protein NS2-3, which is essential for the intracellular replication of the 
virus, is antigenically conserved between all pestiviruses (Sandvik T., 1995; Kuijk H.,  
et al., 2008).    
 
Virus Neutralization test (VN) 
This assay is sensitive and specific for detection of antibodies to BVDV, and it 
has been recognized as the reference test for BVDV serology (Seki Y., et al., 2007). 
The VN test is a biological in vitro system, which quantifies the inhibitory effect of 
specific antibodies on virus replication in cell cultures. The test is usually performed 
in 96-well microtitre plates, where serially diluted sera are incubated with a CP 
challenge virus before susceptible bovine cells are added, for finally incubated with 
the neutralized virus for 4 days (Schefers J., et al., 2008). The antibodies detected 
by VN are predominantly against E2, which may result in different titres depending 
on which virus strain is used in the assay. Because of the high specificity of the test, 
it is essential to use a challenge virus antigenically similar to the field viruses in the 
population to be tested. Established reference strains such as the NADL or Oregon 
C24V are both BVDV-1a, and if the predominating field virus strains differ 
antigenically from these, a cytopathogenic local virus isolate may be a better choice 
if a high sensitivity is desired. In addition, a BVDV-2 virus may be useful as a second 
VN challenge virus, since it represents the antigenically most distantly related BVDV. 
When calibrated properly, VN is a very specific and sensitive assay. However, it is 
labour intensive, requires substantial investments in selection and monitoring of cells 
cultures and media to give satisfactory test results, and therefore, it is not suitable 
for examination of few or sporadic samples (Sandvik T., 2005; Seki Y., et al., 2007). 
 
Enzymed-Linked Immunosorbent Assay (ELISA) 
The measurement of antibody responses of animals exposed to BVDV either 
through a natural exposure or an immunization protocol is still a standard procedure. 
Several ELISAs for detection of BVDV specific antibodies have been available 
commercially since the early 1990s. For BVDV serology they have become popular 
for several reasons: they are independent from cell cultures, they can easily be 
applied for mass screening and results can be read in few hours (Sandvik T., 2005). 
Generally, It has been shown that the prevalence of seropositive animals in herds 
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with one or more PI animals is high, ranging from 53 % to 98% (Waldner CL., et al., 
2005) compared with those herds without PI animals (Thobokwe G., et al., 2004). 
For studies at the animal level, most ELISAs have been developed for the 
detection of antibodies to  BVDV in serum. However, for screening non-vaccinated 
herds, ELISAs for antibody detection in bulk tank milk have been the method of 
choice, being the most economic procedure available for milk herd screening and 
reporting a sensitivity and specificity of  97.9 and 99.7%, respectively (Greiser-Wilke 
I., et al, 2003; Solis-Calderon JJ., et al., 2005). An ELISA based on a monoclonal 
antibody against non-structural protein NS2-3 using milk samples has shown a 
sensitivity and specificity of  95 and 97.7% respectively (Beaudeau F., et al., 2001). 
ELISA to detect BVDV in bulk milk has been recognized as a valuable tool to 
estimate the prevalence of infected animals in the concerned herd, and 
consequently, to identify both BVDV-free dairy herds and herds suspected of 
harbouring an active infection (Niskanen R., 1993). This methodology is currently 
used to identify uninfected herds in the BVDV control and eradication programmes 
developed in Scandinavian countries (Lindberg and Alenius, 1999). High 
absorbance values obtained have been correlated with the prevalence of BVDV-
positive cows in a herd, obtaining four groups of herds: Herd classes 0 and 1 
(characterized by low OD values) which represent herds with absence of infection 
and herds without recent contact with PI animals, and Herd classes 2 and 3 (high 
OD values) that represent herds with recent contact with PI animals and active 
infection and herds with the presence of lactating PI animals respectively. For the 
identification of the single PI animals in Herd classes 2 and 3, individual serum 
samples have to be analyzed by ACE or RT-PCR (Greiser-Wilke I.,  et al., 2003). 
In the Table 4 are present the different tests that could be used in different 
situations of infection in a given herd.  
 
9.3. Role of the  maternal antibodies in the detection of PI animals  
When maternal antibodies to BVD virus are present in the blood of PI calves, 
VI carried out on peripheral blood or on post-mortem specimens may be falsely 
negative (Palfi V., et al., 1993). A predictive study to help to define the proper age to 
avoid BVDV maternal antibody interference,  estimates that it took calves 141 days 
to become seronegative from BVDV type 1 antibodies and 114 days for BVDV type 
2. Colostrum may contain virus neutralizing antibodies with titres higher than 
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1:500,000 and those antibodies may interfere with BVDV antigen detection (Endsley 
JJ., et al., 2003). Some results clearly show that a high proportion of  PI animals 
tested during the first week after the ingestion of colostrum with VI and ACE are 
negative. There is a clear relationship with the maternal antibody status, thus, in the 
presence of high levels of maternal antibodies, the VI and the ACE tests are 
unreliable indicators of the presence of persistent infections with BVD virus (Palfi V., 
et al., 1993). However, the RT-PCR test gave positive results even in the presence 
of high antibody titres, demonstrating the suitability of this test for use in eradication 
programs (Zimmer GM., et al., 2004).  
9.4. Screening acute infections  
For animals that are still alive, the most recommendable sample to detect 
BVDV is whole blood (Saliki JT., et al., 2004). In acute infections, detectable virus 
remain in mononuclear cells two or three times longer than in serum. To be 
successful using serum from an acutely infected animal, the sample would need to 
be collected 3 to 8 days post-infection. Because the date of infection is rarely known, 
this narrow range of viremia makes difficult to establish the best time for sampling. 
Swabs of mucosal surfaces can also be a successful sample for detecting BVDV, 
particularly in early phase of infection (Tajima M., et al., 2008). Paired serum 
samples for measuring the titer of neutralizing antibodies is still the current norm. 
Sampling of non affected animals for comparison is often recommended, particularly 
when no previous testing in the herd has been carried out.  
If clinical signs are due to the MD syndrome, the sampling recommendations 
for acutely infected animal are still valid. Because a true case of MD begins with a PI 
animal, virus is present in virtually any sample collected (Luzzago C., et al., 2006; 
Hilbe M., et al., 2007a). Ear notches should be collected from affected animals to 
define the disease status. In the vast majority of cases, acutely infected animals will 
not have a significant amount of antigen in the skin tissue (Walz PH.,  et al., 2001; 
Brodersen BW., 2004).  
9.5. Screening persistent infections 
The PI animals represent less than 1% of the bovine population (Brock KV, 
2003; Campbell JR., 2004). Some possible testing scenarios are present in Table 5. 
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Table 4. Suggested Diagnostic Laboratory tests for given testing situations (Larson RL., et al., 2005) 
 
SITUATION TEST RATIONALE 
Testing sick suckling calves 
(pneumonia, septicaemia, etc.) for 
possible  BVDV involvement 
*IHC or ACE for skin samples to identify PI 
and sometimes TI animals 
*PCR of blood or serum to identify PI and TI 
animals 
*Maternal Antibodies may interfere 
with VI and ACE using serum or 
plasma. 
*If negativity is observed in ACE or 
IHC and positivity in PCR from blood 
or serum, TI  infection is likely. 
Testing dead suckling calves for BVDV 
possible involvement 
*IHC or ACE for skin samples to identify PI 
and sometimes TI animals 
*IHC, FA or VI from tissues to identify infected 
calves (no difference between PI and TI 
animals) 
 
*Maternal Antibodies may interfere 
with VI and ACE-ELISA using serum 
or plasma. 
*If a dead calf is IHC or ACE negative 
from skin sample, but positive from a 
tissue sample, TI is likely. 
Screening a herd (suckling calves, cows 
that lost calves, replacement animals) 
because there is laboratory evidence of 
BVDV in the herd 
*IHC or ACE for skin samples to identify PI 
and sometimes TI animals 
 
*Maternal Antibodies may interfere 
with VI and ACE-ELISA using serum 
or plasma. 
Screening open replacement heifers 
(raised or purchased), purchased open 
cows, or bulls raised or purchased 
*IHC or ACE for skin samples to identify PI 
and sometimes TI animals 
*PCR- pool serum or whole blood into groups 
of  30-40 or less. Test individual skin samples 
of animals in positive pools to identify PI’ s. 
Animals in negative pools are considered not-
PI. 
Any positive result could be  confirmed 
by using IHC, ACE, VI or PCR of 
serum or blood samples taken no less 
than 21 days later. 
Screening purchased pregnant 
replacement heifers or cows prior to 
entry into the herd 
*IHC or ACE for skin samples to identify PI 
and sometimes TI animals 
*PCR- pool serum or whole blood into groups 
of 30-40 or less. Test individual skin samples 
of animals in positive pools to identify PI’ s. 
Animals in negative pools are considered not-
PI. 
*Isolate pregnant animals away from resident 
herd until the calf is born and tested for PI 
status via IHC or ACE from skin samples. 
Any positive result could be  confirmed 
by using IHC, ACE, VI or PCR of 
serum or blood samples taken no less 
than 21 days later. 
 
 
Screening raised replacements heifers 
and bulls prior to sale by a supplier 
*IHC or ACE for skin samples to identify PI 
and sometimes TI animals 
*PCR- pool serum or whole blood into groups 
of 30-40 or less. Test individual skin samples 
of animals in positive pools to identify PI’ s. 
Animals in negative pools are considered not-
PI. 
 
Any positive result could be  confirmed 
by using IHC, ACE, VI or PCR of 
serum or blood samples taken no less 
than 21 days later. 
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Table 5. Suggested diagnostic laboratory tests for the detection of PI animals (Larson RL., et al, 2004) 
TEST COST ADVANTAGES DISVANTAGES SPECIMENS/SHIPPING 
Virus isolation 
1-3 week turnaround 
Moderate to 
high cost 
-Gold standard for BVDV 
-High specificity 
-Virus is available for 
study at a later date 
-Slow procedure 
-Labor-intensive 
-Potential false 
negative due to 
interference by 
maternal Ab 
-Retest positive 
animals in 3-4 
weeks to 
distinguish 
between PI and TI 
-Whole blood (10 m) or 
serum (2-3 ml) 
-Send in container  with cold 
packs. 
-Do not freeze the samples  
Immunohistochemistry 
(IHC) 
2-5 day turnaround 
Low cost 
-High sensitivity 
-Usually identifies only PI 
TI usually test negative 
-Labour-intensive 
-Formaline usage 
-Will not generally 
identify TI animals 
-Skin samples-ear notch 
-Send fresh on wet ice or 
stored in 1:10 volume of 10% 
neutral buffered formalin 
-Sample can be held in 
formalin for several weeks 
 
Antigen-Caputure ELISA of 
serum 
1-2 day turnaround 
Low cost 
-High sensitivity 
-Easy to carry out 
-Potential false 
negative due to 
the interference by 
maternal 
antibodies 
-Variation of 
viremia 
-To distinguish 
between PI and TI 
animals, retest 3 
weeks later 
-Serum (2 ml) 
-Send in insulated container 
with cold packs. 
Antigen-Caputure ELISA of 
skin 
1-2 day turnaround 
Low cost 
-High sensitivity 
-Usually identifies only PI 
TI animals usually test 
negative 
-Will generally not 
identify TI animals  
-Skin samples-ear notches 
-Send in insulated container 
with cold packs. 
-Do not allow to dry out 
Antigen-Caputure ELISA of 
tissue / leukocytes 
1-3 day turnaround 
Low cost -High sensitivity 
-Labor-intensive to 
prepare  buffy coat 
-Not used in a 
large screening 
-Whole blood (10 ml) using 
EDTA or heparin 
-Tissues  
-Send in insulted container 
with cold packs. 
Polymerase chain reaction 
(PCR) 
1-3 day turnaround 
-Moderate to 
high cost (can 
be reduced 
pooling 
samples) 
-High sensitivity 
Can detect 1 ng/ml BVDV 
RNA 
 
-Potential of false 
positive due to 
laboratory 
contamination 
-Retest samples in 
3 weeks to 
distinguish 
between PI and TI 
animals 
-Whole blood (10 ml) or 
serum (2-3 ml) 
-ear noches in red top tubes 
-milk, semen and tissues 
-Send in insulted container 
with cold packs. 
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10. CONTROL  
A general model for successful BVDV control is proposed in Fig. 8. Three 
necessary elements are identified: bio-security, virus elimination and monitoring 
(Lindberg A. and Houe H., 2005). 
 
                      
 
Fig. 8.  General model for systematic control of BVDV. Bio-security, virus elimination and monitoring are necessary 
 
In the context of BVDV control it is helpful to distinguish between non-systematic 
and systematic approaches. After the pivotal role of PI animals for the perpetuation 
of BVDV infection had been recognised, the removal of these animals from infected 
herd became the most important control (Ellis JA., et al., 1995; Hilbe M., et al., 
2007). However, as long as vaccination and removal strategies are being used 
exclusively on herd basis without systematic follow-up or monitoring the outcome, 
they can only be described as non-systematic. In contrast, systematic control implies 
a goal-oriented reduction in the incidence and prevalence of BVDV infections, 
typically implemented on a regional or national level (Reichel MP., et al., 2008). 
 
10.1. Non systematic control -Vaccination 
For a long time, the purpose of vaccination was the prevention of acute clinical  
diseases in herds. The crucial issue of breaking the infectious cycle by preventing 
the generation of new PI animals was long neglected or not even addressed. Only in 
the 1990ies the importance of intrauterine protection as a primary goal of vaccination 
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became clear. In many countries vaccination is widely used and many different 
vaccines are available. However, there is no indication that vaccination alone has 
ever resulted in decline of BVDV prevalence. In summary, non-systematic control 
efforts may well result in improved animal health and prevent BVDV associated 
losses. However, their efficacy is mostly restricted to the herd level, usually for a 
limited time period, and no decrease of the overall BVDV prevalence can be 
expected (Greiser-Wilke I., et al., 2003; Moennig V., et al., 2006; Houe H., et al., 
2006). 
10.2. Systematic control  
The first systematic control/eradication schemes were successfully developed in 
Scandinavian countries in the early 1990s. Later, some other European countries or 
regions followed by Scandinavian example by implementing similar control regimes 
for the control of BVDV.  The identification and removal of PI animals as well as the 
prevention of new infectious with BVDV are key elements of this kind of control and 
could be developed with and without vaccination (Ståhl K., et al., 2005; Hult L., et al., 
2005; Houe H., et al., 2006).  
Systematic control without vaccination 
Initial test for classification of herd status: 
• Implementation of additional biosecurity measures. 
• Follow-up tests for identification and removal of individual infected animals in 
infected herds. 
• Continued monitoring of supposedly free herds to confirm a free status 
and/or for rapid detection of any new infection. 
In a non-vaccination environment a herd diagnosis can be performed by 
assessing the serological situation. The goal is to detect the presence or absence of 
antibodies against BVDV. The diagnosis can be based on testing antibodies in bulk 
milk, in individual or pooled serum samples from young stock or in pooled samples 
(milk or serum) from primiparous cows and the virus detection in bulk milk (by PCR) 
(Mars MH., et al., 2005). 
The first systematic programmes aimed at eradicating BVDV without the use of 
vaccines were launched in 1993-1994 in Denmark, Finland, Norway and Sweden. 
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Despite different preconditions in terms of initial prevalence of herd with PI animals 
varying from 1% in Finland to 50% in Denmark it has taken all countries 
approximately 10 years to reach their final phases. First to reach eradication will 
most likely be Norway (Rikula U., et al., 2005). Austria has followed the 
Scandinavian example and after seven years, approximately 30% of them targeted 
herds are certified as being free for BVDV (Rossmanith W., et al., 2005). 
Systematic control efforts have also been implemented in other parts of Europe, 
such as on the Shetland Islands were BVDV has been eradicated, and in Brittany 
(France), in The Netherlands (Mars MH., et al., 2005) and Germany (Moennig V., et 
al., 2005). Time-limited,  project type control efforts have been implemented in the 
Rome area, and in the Lecco and Como regions of Italy (Ferrari G., et al., 1999; 
Luzzago C., et al., 2001). It should be noted that the only approaches that emphasis 
on biosecurity  in general, and control of direct animals contacts in particular with or 
without the complementary use of vaccines.   
In a given herd under systematic protocol, a BVDV biosecurity guidelines on 
how to avoid re-infection relevant to the cattle population in question is necessary. It 
is important to identify and remove PI animals as fast as possible in order to reduce 
the risk of transmission (if it is possible, testing them before colostrum is given). 
Undetected PI animals are thus a source of new infections and it is essential to 
avoid the contact between susceptible dams in early pregnancy and PI animals. A 
common source or re-infection is accidental reintroduction from infected herds. If 
pregnant replacement animals of unknown BVDV status are to be introduced into a 
herd cleared of BVDV, they should be kept in quarantine facilities until they are 
verified free from the disease. Other means of infection are biologic products, 
including semen, embryos, colostrum, vaccines and other veterinarian drugs used. 
Similar visitors clothing, equipment or other fomites should be monitored with regard 
to possible BVDV contamination. Recommendations on use of disinfectants should 
be readily available to farmers (Houe H., 1995; Sandvik T., 2004; Smith DR., et al., 
2004; Luzzago C., et al., 2008). 
Systematic control with  vaccination 
Under circumstances where the Scandinavian approach of eradication might not 
be applicable for several reasons, systematic vaccination after removal of PI animals 
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is an option in order to minimize the risk of re-introduction of the virus into cleared 
herds. The programme comprises the following elements (Moennig V., et al., 2006): 
• Initial test for classification of herd status, identification and removal of PI 
animals. 
• Follow-up tests for identification and removal of PI calves born within the first 12 
months after clearance of infected herds.  
• Systematic vaccination using a vaccine and protocol with a proven record to 
protect pregnant animals against foetal infection. 
• General and individual biosecurity measures. 
Since vaccination might interfere with bulk milk testing, initial screening of herds 
depends on the epidemiological situation. In vaccinated herds, a few animals older 
than 6 months should be kept unvaccinated so they can work as sentinel animals for 
indications the infection pressure in the herd (Moennig V., et al., 2005a). The option 
to identify PI animals in dairy herds could be the PCR in milk samples and in positive 
cases, PI animals will be identified individually.  The rest of the herd can be tested 
either using individual or pooled blood samples or ear notch samples that will be 
analysed using ACE or RT-PCR ( Mars MH., et al., 2005; Kennedy JA., et al., 2006 
a and b). 
When all PI animals have been removed, systematic vaccination, preferably a 
two step control is implemented. Depending on the epidemiological situation, 
vaccination can be mandatory or banned. In areas with high density of cattle, intense 
trade, sub-optimal control of biosecurity and a high prevalence of BVDV, systematic 
vaccination should be used until the incidence of PI cattle has reached a low level. In 
areas with low BVDV prevalence, vaccination should be banned because the risk of 
re-introduction of BVDV into free herds is likely to be low. In any case, continued 
monitoring is an essential element of the program (Lindberg A., et al., 2006; 
Kalaycioglu AT., 2007). 
Finally, the predictors for the efficiency with which control measures can 
systematically reduce the prevalence of BVDV infections are: the ability to prevent 
new infections, the ability to rapidly detect new cases of infection, the ability to 
intervene in infected herds (efficiency of diagnostic), strength in incentive to clear 
infected herds, the ability to get acceptance of/compliance of the programme, 
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collaboration between the farmer’ s organizations, strength in support from 
authorities through legislation and impact of market effects (Lindberg A., et al., 2005; 
Moennig V., et al., 2006). 
 
11. PROFILAXIS  
BVDV vaccines are important component of BVDV prevention and control 
programs. For decades, the majority of vaccines contained only biotype 1 BVDV, but 
due to the widening diversity of field BVDV strains, the animal health industry has 
responded in two ways: adding both, 1 and 2  BVDV genotypes to vaccines, or 
performing cross-protection studies with vaccines containing a type 1 vaccines 
(Kelling CL., 2004). Because BVDV vaccines should protect against systemic 
infection with a range of antigenic variant strains of BVDV isolates, some important 
variables to consider when selecting a vaccine include the immune response, 
crossreactivity, fetal protection, duration of immunity, immunosuppression, reversion 
to virulence and effect of maternal antibody on immune response and purity (Chase 
CC., et al., 20004; Platt R.,  et al., 2008). 
 
11.1. Modified-lived virus vaccines (MLV) 
 The major advantage of MLV is the stimulation and production of relatively 
high concentrations of viral neutralizing antibodies, correlating with protection in 
future exposure with virulent virus (Ellsworth MA., et al., 2003). Generally, MLV 
actives all phases of the immune system, yielding a balanced systemic and local 
immune response and a balanced humoral and cell-mediated response (Reber AJ., 
et al., 2006). Some studies have shown that vaccinating with a MLV using both 
BVDV genotypes, it is possible to increase cell-mediated immune memory response, 
meanwhile others researches report that the vaccination only with BVDV type 1 
provide cross-protection against type 2 BVDV challenges. Crossreactivity of 
antibody induced in response to MLV BVDV vaccines was demonstrated, where 
vaccinated cattle produced antibodies by three weeks that neutralized different 
strains of BVDV in vitro (Fulton RW., et al., 2003). In the same way, experimental 
challenge-exposure experiments have been conducted to confirm that MLV type 1 
vaccines crossprotect young calves from experimental infection with a virulent strain 
of BVDV type 2 (Kelling CL., et al., 2004 and 2007).  In contrast, some studies have 
demonstrated that CP BVDV type 1a failed to provide type 2 BVDV protection. In 
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some way,  some cross protection is afforded by BVDV single strain, but the wide 
antigenic diversity and different clinical syndromes of BVDV strains requires the use 
of more than a single strain to develop high levels of protection on the field (Dean 
HJ., et al., 1999).  
Stressed cattle should not be vaccinated with MLV BVDV vaccines, because  
this vaccines in some cases can induce prolonged suppression on the host defense 
mechanisms. Features as the potential risk of shedding BVDV after vaccination with 
MLV, followed by the transmission to susceptible contact animals and the reversion 
to virulence have been examined experimentally. In one study, calves vaccinated 
with MVL develop a transient viremia and nasal secretion for several days (Kelling 
CL., 2004). The maternal antibodies in calves play an important role on their efficacy 
when they are present in high concentrations, due to the block of an adequate 
protective immune response (Zimmer GM., et al., 2004). 
 
11.2. Inactivated vaccines 
 The major advantage of inactivated BVDV vaccines is that they are safe, do 
not produce immunosuppressive effects and they are not fetopathogenics. The 
principal disvantages are that they generally induce a weaker neutralizing antibody 
response, a shorter duration of protection and a limited cytotoxic T-cell response, 
which plays an important role in recovery and resistance to disease (Makoschey B., 
et al., 2001; Platt R., et al., 2008). In the case of inactivated BVDV vaccines, they 
have shown to confer high protection only to the specific strain used and a very low 
response to different genotypes. Some studies have shown that inactivated type 1a 
vaccines provided only 78% of protection against a type 1a challenge, 63% of 
protection against 1b type challenge and no protection against  BVDV type 2 
challenge.  
 
11.3. DNA and recombinant vaccines  
Lately, DNA and recombinant viral vector vaccines have been created and 
tested on an experimental level to develop a vaccination strategy to overcome the 
shortcomings of MLV and inactivated vaccines. BVDV vaccines encoding the type 
1a E2 protein have been tested in mice and cattle, and they induce the formation of 
neutralizing antibodies and cell-mediated immune response, followed by B-cell 
memory, but unfortunately they have offered limited protection in cattle challenged 
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with an heterologous BVDV type 1b strain. Recombinant BVDV immunogens 
expressing structural glycoproteins E0, E1 and E2 have been produced and tested 
in cattle, observing a high induction of neutralizing antibodies against the 
homologous strain as well as against heterologous strains in a very efficient way 
(Chimeno ZS., et al., 2007). In other hand, calves  immunized with a plasmid 
encoding either BVDV type 1 and 2 E2 glycoprotein and consecutively challenged 
with BVDV-2 strain, developed both humoral and cell-mediated immune responses, 
including virus-neutralizing antibodies and IFN-gamma-secreting cells in the 
peripheral blood. Additionally, animals  presented little leucopenia and no weight 
loss or temperature response (Young NJ., et al., 2007; Liang R., et al., 2008). 
 
11.4. Foetal protection  
The principal goal to improve the vaccination scheme in the cattle is the 
prevention of the developing fetuses infected with BVDV, principally PI animals 
(Ellsworth MA., et al., 2006). Foetal protection with two different MVL vaccines 
containing single type 1 BVDV provided protection that varied from 83 to 92% 
against type1 BVDV challenge, but only 58% against type 2 challenge (Kovács F., et 
al., 2003; Brock KV., et al., 2006). This lack  of strong cross protection has been also 
seen in field cases.  In other hand, using a MLV vaccine containing two BVDV 
strains type 1a (Singer) and type 2, it was possible to observe a foetal protection of 
100% in the challenge with type 1,  and 95% against type 2 challenge (Chase CC., 
et al., 2004). In a study aimed on the determination of the efficacy of an inactivated 
BVDV vaccine in preventing fetal infection, it was obswerved that 36% of fetuses 
from dams vaccinated pre-breeding with inactivated vaccine, and experimentally 
challenge-exposed between 80 and 90 days of gestation, were protected against 
BVDV infection. Inactivated vaccines should contain more than a single strain to 
develop cross reaction in the field (Zimmer GM., et al., 2002; Kellying CL, 2004).    
In contrast, using inactivated BVDV vaccine followed by vaccination with MVL 
BVDV vaccine, it was established that heifers intranasally challenged 4 weeks after 
the second vaccination (between 30 and 120 days of gestation) with a mixture of 
type 1 and type 2 BVDV isolates, delivered clinically healthy seronegative and 
BVDV-free calves (Greiser-Wilke I., et al., 2003). After these researches, a “ Two-
steps”  vaccination is recommended and available everywhere (Moennig V., et al., 
2005). First vaccination is carry out using and inactivated vaccine,  and four weeks 
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later a booster vaccination is applied using a MLV. This protocol ensures a long-
lasting immune response and a comprehensive foetal protection. It has never been 
observed that MLV virus is shed when used in the context of two-step vaccination.  
Animals must be vaccinated at the latest eight weeks before their first pregnancy. 
Authors suggest that a group of young animals older than 6 months could kept 
unvaccinated and monitored for BVDV antibodies to confirm that there is no new 
introduction of infection (Frey HR., et al., 2002; Oguzoglu TC., et al., 2003). 
A general vaccination program can be implemented in healthy replacement 
heifers (isolated from pregnant cows) based on the twice administration of BVDV 
MLV before breeding. Vaccination should be timed so that maximal protection is 
afforded during the critical first 4 months of gestation to maximize the potential of 
adequate duration of immunity. MLV should be administrated 60 days before 
breeding. If inactivated vaccines are used instead of MLV products, vaccination of 
heifers before breeding should be timed so that maximal response are achieved. 
The second dose of the primary series should be administrated 2 weeks before 
breeding. Cows should be revaccinate annually, principally 2 weeks before breeding 
(Kellying CL., 2004).  
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1. INTRODUCTION 
BVDV is a significant pathogen associated with gastrointestinal, respiratory, 
and reproductive diseases of cattle worldwide. The ability of BVDV to cross the 
placenta during early pregnancy can result in the birth of PI calves, which are 
capable of shedding large quantities of virus throughout their lives and are 
considered the primary reservoirs for BVDV. For this reason, the detection of the 
principal sources of infection (PI animals) is the important key in the control of the 
disease spreading (Kelling CL., 2004; Lindberg A. and Houe H., 2005). PI animals 
do not show antibody response and diagnostic tests such as virus isolation, IHC, 
Antigen-Capture ELISA, and RT-PCR are used in their detection (Cornish TE.,  et 
al., 2005; Sandvik T., 2005). Control efforts based on the  identification and  
elimination of PI animals have been successful in a number of countries around the 
world. In Italy, little  research has been done about BVDV seroprevalence and  at 
this time no compulsory/voluntary control program exists in order to detect  and 
eliminate PI animals. BVDV-1 is the predominant and most wide distributed 
genotype in the north of the country, where 30% of the bovine population is 
concentred. In particular, BVDV-1b is the most frequently isolated, followed by 
groups c, d and e (Luzzago C. et al., 2001; Falcone E. et al., 2001 and 2003). In 
contrast, BVDV-2 genotype  has been isolated from 2 healthy animals from a farm in 
the northern Italy where a several outbreak originated for the use of Herpesvirus-1 
MLV contaminated with BVDV-2 strain (Falcone E. et  al., 1999; Luzzago C. et al., 
2001). The importance to study the seroprevalence in central regions and the 
identification and segregation of BVDV genotypes that are present in infected and PI 
animals in Italy, could be a significant research to understand the distribution and the 
movement of the virus in the different regions of the country, and also can contribute 
with important information to understand the epidemiology of the disease aimed to 
future control programs that could be developed in this country.  
 
2. Study design  
The aim of this study was to compare the different techniques used routinely in 
the detection of BVDV infected and PI animals. Following that objective, the first step 
was to contact cattle farms that were agree to collaborate in a voluntary BVDV 
eradication program based on the detection and elimination of PI animals. In the 
farms included in the study, an important anamnesis was carried out. Sera samples 
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were obtained from animals in each herd and were tested using a commercial 
Antibody BVDV ELISA kit in order to detect the presence of antibodies against 
BVDV. Seropositive animals were considered infected (if not vaccinated) or with a 
post-vaccination immune response, being excluded as PI candidates. In other hand, 
all seronegative and young animals (< 2 years old) were considered as possible PI, 
and were tested to detect BVDV antigen in sera samples with a commercial kit  
Serum/Antigen-Capture ELISA (serum/ACE). The criteria of choosing animals 
younger than 2 years old is because PI animals are susceptible to suffer secondary 
diseases, and generally die before reach 2 years old. In order to  standardize a RT-
PCR protocol, RNA  from four BVDV infected cell-cultures (one genotype 1 and 
three genotype 2) were used as positive controls. Three PCRs were standardized 
using specific primers that amplifies a high conserved region of the 5’ UTR, one 
targeting the Pestivirus  genus and two for differentiate between BVDV genotypes 1 
and 2. Sera samples from seronegative and young animals were pooled (5 
samples/pool) and tested with the RT-PCR standardized, and if a positive pool was 
obtained, samples of the pool were tested individually. Finally, If seronegative/ 
antigen positive animals were detected, they were inserted in a second sampling 
plan consisting in buffy coat, ear notch and tissues samples (if animals were culled) 
for being tested with other techniques as Leukocyte/ACE,  IHC  and RT-PCR. 
 
3. Farms and animals sampled    
An epidemiological form was created (Annex 1) based on different researches 
that have measured the principal risk factors associated with the presentation of the 
BVDV and the presence of PI animals in farms in different countries (Luzzago C. et 
al., 1999; Ferrari G. et al., 1999; Nuotio L. et al., 1999; Biuk-Rudan N. et al., 1999; 
Obando C. et al., 1999; Mainar-Jaime RC. et al., 2001; VanLeeuwen JA. et al., 
2001; Stahl K., et al., 2002; Mockeliuniene V. et al., 2004; Solis-Calderón JJ. et al., 
2005; Niza-Ribeiro J. et al., 2005). For a better understanding of the dynamic of 
BVDV infection and for the possibility to identify recent infections within farms,  
animals were categorized by age (in months) in two groups: younger and older than 
24 months old.  In general, if  young animals are infected, there is a high possibility 
that some PI animals are spreading the disease and causing recent or on-going 
infections in the farm. In the same way, another important and useful information as 
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sex, breed, clinical history of the farm and introduction or movement of animals 
inside the farms was collected.  
A total number of 21 farms were sampled. Twenty were unvaccinated farms (10 
were originally from Lazio, 6 from Umbria and 4 from Marche regions), representing 
the 91.96% (1774/1929) of sampled animals. Only one farm (Umbria’ s region) was 
applying a vaccination program against BVDV. The total number of animals sampled 
was 1,929, and their age, breed, sex and other characteristics are shown in the 
Table 6.  All animals  sampled were Holstein Friesian  females.  According to the 2 
groups of age, 73.25 % (1413/1929) of animals sampled were older than 24 months 
and 26.74% (516/1929) were younger than 24 months old. 
  
Table 6. Principal characteristics of  farms and animals studied in the research 
Age 1 No. 
Farms 
Region Vaccination 
No. of 
animals < 24 m > 24 m 
Breed 2 Sex 3 Observation 
10 Lazio No 821 269 552 HF F Monitoring 
6 Umbria No 624 132 492 HF F Monitoring 
4 Marche No 329 85 244 HF F Monitoring 
20 
  
1774 486 1288   
 
1 Umbria Yes 155 30 125 HF F Monitoring 
  
 
 
    
 
21 
  
1929 516 1413   
 
    
1m: months;   2 HF: Holstein Friesian;  3 F: Female   
 
 
4. Serology and Antigen Detection 
BVDV ANTIBODY DETECTION. Samples of blood (6 ml) were collected in tubes 
without anticoagulant and centrifuged at  2500 rpm for 20 minutes in order to obtain 
sera samples. The sera were refrigerated and tested as soon as possible using a 
commercial kit IDEXX HerdCheck ELISA BVDV Antibody Test. The test was realized 
following the manufacturer’ s instructions. Briefly, the kit requires the sera 
incubation in antigen-coated wells with BVDV antigen (NS 2-3 protein).  After 90 
minutes of incubation at room temperature, captured BVDV antibodies were 
detected by anti-bovine horseradish peroxidase conjugate. Unbound conjugate was 
washed away and substrate/chromogen solution was added. In the presence of 
enzyme, substrate was converted into a product which reacts with the chromogen to 
generate a blue color. Upon addition of stop solution, a yellow color was generated. 
The optical density (OD) of the plate was measured using a spectrophotometer 
(Labsystem Multiscan) at a single wavelength of 450 nm .   
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ANTIGEN DETECTION. Both immunoassay, Serum/ACE and Leukocyte/ACE 
are based on the detection of structural glycoprotein Erns of BVDV through the use of 
monoclonal antibodies (MAbs). In Serum/ACE, sera samples  were incubated in the 
plate for 2 hours at 37°C or overnight at 4°C. If in the serum the antigen was 
present, this was captured on the plate by MAbs. After incubation of the test sample 
in the well, captured antigen was detected by specific antibodies and horseradish-
peroxidase conjugate. Then, unbound conjugate was washed away and 
substrate/chromogen solution was added. In the presence of enzyme, substrate was 
converted into a product that reacts with the chromogen to generate a blue color. 
Upon addition of the stop solution, a yellow color was generated. The optical density 
(OD) of the plate was measured using a spectrophotometer (Labsystem Multiscan) 
at a single wavelength of 450 nm .   
In Leukocyte/ACE,  buffy coat and tissue samples were processed before their 
use. To obtain buffy coat samples, 5 ml of cold (2-8°C) 0.17M NH
4
CL were added in 
a 10 ml centrifuge tube with 5 ml of EDTA blood, and left for 10 minutes at room 
temperature. After this step, the tube were filled with cold (2-8°C) distilled water, 
mixing gently and centrifuged at 1500g for 5 minutes. The supernatant was 
discharged and an equal quantity of sample diluent included in the kit to the cell 
pellet was added. After this, the pellet was mixed by vortex and left by 1 hour in 
room temperature. Finally the tube was centrifuged at 1500 g for 5 minutes and the 
supernatant was used in the test protocol. In case of tissue samples, 2 grams were 
cut in small pieces and in a 10 ml tube were added 5 ml of sample diluent (included 
in the kit), vortexed and left 1-2 hours at room temperature. After this time, the 
samples were centrifuged at 1500 g for 10 minutes and 50µl of the supernatant were 
used in the test. Finally, the immunoassay was carried out following the 
manufacturer’ s instructions and using  the same principle than Serum/ACE.  
 
5. RT-PCR  
POOLING SERA SAMPLES. In order to test an economical methodology for the 
BVDV PI cattle screening, pooled serum samples from all seronegative and young 
animals was developed. Knowing that serum may have lower amounts of virus 
compared with other samples, it is recommended to form pools maximum of 10 
samples (Muñoz-Zanzi CA., et al., 2000; Ridhpath JF., et al., 2000; Daly R., et al., 
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2006). Following these recommendations, each pool was formed of 100µl of 5 
samples as previously described (Weinstock D., et al., 2001). Some previous 
experiments have described the detection of BVDV using RT-PCR without RNA 
extraction in different samples as blood, buffy coat and serum samples, establishing  
that this step can be omitted without loosing sensitivity of virus RNA detection 
(Groom J., et al., 1999; Ridhpath JF., et al., 2002;  Deregt D., et al., 2002).  For that 
reason we decide to test the RT-PCR using positive controls with both methods 
(described forward). Pooled samples were tested without previously RNA extraction, 
using 6 µl of each pool directly to RT (Groom J., et al., 1999). Finally and with the 
intend to corroborate the validity of PCR, each test was run with a positive control.   
 
VIRUS USED AS POSITIVE CONTROLS.  Four BVDV cell-culture infected were 
used: one was genotype 1 and 3 were genotype 2. The principal characteristics of 
viruses are present in Table 7. The strains were kindly donated by Prof. Carlo 
Valente (Laboratorio di Virologia V.Cilli, Università di Perugia) and Dr. Gian Mario 
De Mia (Istituto Zooprofilattico Sperimentale Umbria and Marche, Sezione Perugia). 
The cell-culture infected were detached and harvested by the Institution that donate 
them to us. Briefly, from the cell culture, the medium was aspirated to finally wash 
the cells with PBS. Then, PBS was aspired and 0.25% of Trypsin was added. Once 
the cells were detached from the flask, medium was added (containing serum to 
inactivate the trypsin) and the cells were transferred to a RNAase-free eppendorf  
tube. The total number of cells was unknown. Finally, this material was used for the 
RNA extraction or was stored at -80°C until their use. 
 
Table 7. Principal characteristics of virus used in the research 
Virus Genotype 
Year of 
isolation 
Cell culture Origen Characteristic 
NADL 1 - BFK a ATCC Respiratory disorders 
TMV-2 (a) 2 1967 MDBKb Nasal swab Respiratory disorders 
TMV-2 (b) 2 1985 BFK c Spleen Digestive disorders 
BVDV-2 2 1970 BFK Spleen Digestive disorders 
 
BFK: Bovine Fetal kidney; MDBK: Madin-Darby Bovine Kidney,  a10 passages; b Fourth passage c 32 passages  and then 
propagated  in  MDBK. This strain was originated from TMV-2 (a) 
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PRIMERS USED FOR THE cDNA AMPLIFICATION AND PCR. Few works have 
used as a target the sequences of structural and non-structural proteins of the BVDV 
genome, but the results obtained have shown an important ranges of variability. In 
other hand, those works that have used as a target the 5’ UTR  of the genome, 
considered as a highly conserved among Pestivirus, have shown better results 
about sensitivity and specificity. Due to the description of the universal Pestivirus 
primers widely used by different authors, their use in different clinical samples and in 
addition the acceptable results obtained about sensibility, we decide to use the 
universal primers which amplify a product of 287 pb of the 5’ UTR  of the Pestivirus 
genus (Leteiller C. et al., 1999). In the same way, primers B3/B4 and B5/B6 were 
used to amplify and differentiate between genotypes 1 and 2 respectively. Both set 
of primers amplify a product of 221 pb (Table 8).   
 
Table 8. Primers used to detect Pestivirus genus and for the detection and differentiation of BVDV 
genotype 1 and 2 
 
 
Primer 
 
Sequence Genome positiona Specificity 
Size of the 
amplified product Reference
b
 
BE 5’-CAT GCC CTT AGT AGG ACT AGC- 3’ 108-127 Pestivirus 
 
287 pb 
(BE / B2) 
1, 3 
B2 5’ –TCA ACT CCA TGT GCC ATG TAC -3’ 395±375 Pestivirus  1,2,3,4,5 
B3 5’- GGT AGC AAC AGT GGT GAG- 3’ 139±155 BVDV type I 
 
221 pb 
(B3 / B4) 
1 
B4 5’ - GTA GCA ATA CAG TGG GCC - 3’ 360±343 BVDV type I  1 
B5 5’ - ACT AGC GGT AGC AGT GAG -  3’ 139±145 BVDV type II 
 
221 pb 
(B5 / B6) 
1 
B6 5’ -  CTA GCG GAA TAG CAG GTC - 3’ 360±343 
 
BVDV type II 
 
 1 
a
 According to the NADL genome position 
b
 1) Letellier C., 1999;  2) Letellier C.,  2003   3) Groom J. et al, 2001  4) Toplak I. et al., 2004  5) Luzzago C. et al., 2001 
 
Primers were carefully analyzed the nucleotide sequence, the right genome 
position and the right size of amplified product using the Genbank program 
(http://www.ncbi.nlm.nih.gov/Genbank). Finally, the specificity of each primer was 
corroborated using the BLAST program (http://www.ncbi.nlm.nih.gov/BLAST/), which 
practically compare similar nucleotide sequences in the same and different organism 
that we are studying. In this way, the primers chosen were highly specific to the 
5’ UTR of Pestivirus genus, and to the BVDV 1 and 2 genotypes respectively.  
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RNA EXTRACTION AND cDNA SYNTHESIS. According to different references 
(Luzzago C. et al., 2001; Toplak I., et al., 2004), RNA was extracted from 100 and 
200µl of each virus-infected cell culture. Due to the high risk of degradation and the 
low stability of RNA, the RNA extraction was carried out using a commercial kit 
(QIAGEN RNeasy Mini Kit).  Briefly, the samples were disrupt and homogenized 
with buffer RTL (based on Guanidine Thiocyanate). Then, a volume of ethanol at 
70% was added and the homogenized was transferred to a Rneasy column included 
in the kit  for being centrifuged to discard the flow-through. After adding RW1 buffer, 
which create the conditions that promote selective binding of RNA to the membrane,  
the samples were centrifuged. Two steps of washing with Buffer RPE were realized 
followed by centrifugation. Finally, RNA was diluted in 30µl of Rnase-free water 
included in the kit. RNA was used immediately or stored at -80°C until its use.  
 Using the QIAGEN Omniscript Riverse Transcription kit,  the cDNA synthesis 
was carried in 20µl of total reaction, containing 1X of buffer RT, 0.5mM of each 
dNTP, 1µM of the reverse primer B2 (Vilcek S. et al., 1994; Letellier C., et al., 1999; 
Luzzago C. et al., 2001 and 2003; Toplak I. et al., 2004), 4 Units of Omniscript 
Reverse-Transcriptase and  1, 2 and 3µl of  RNA  were tested. In case of  RT of  
positive controls without RNA extraction, 2 µl were used directly from each BVDV 
cell-infected cultures. In the same way, from sera samples, 6 µl from each pool were 
used directly without previous RNA extraction (Groom J., et al., 1999).  The cDNA 
was synthesized at constant temperature of 37°C in a Hybaid PCR Express 
thermocycler for 60 minutes. Finally, the reverse transcription (RT) reactions were 
tested immediately by PCR.  
 
cDNA AMPLIFICATION. For the Pestivirus  cDNA Amplification, we followed the 
recommendations of a previous research (Leteiller C., et al., 1999). In a 50µl of final 
volume of reaction, the PCR mix contained a final concentration of 1X QIAGEN 
Master mix (10 mM of tris-HCl,  KCl, (NH
4
)
2
SO
4
 , pH 8.7), 200 µM of each dNTP, 
2.5U of QIAGEN Taq DNA Polymerase, 1.5µM of each primer (BE/B2) and  3mM of 
MgCl
2. .
Different quantities of the RT products (1, 2 and  3 µl) of each viral strain with 
and witouth previous RNA exctraction step were tested. In case of pooled sera 
samples, 2 µl of RT were used for the amplification. The amplification program was 
run with a Hybaid PCR Express  thermocycler and the amplification program was 
carried out for 5 minutes at 95°C for an initial denaturation, and then submitted to 35 
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cycles of 94°C for 1 minute, 57°C for 1 minute and 72°C for 1 minute. Additionally, 
different  annealing temperatures  were tested (55, 56, 57, 58, 59, 60°C). A final 
extension step of 72°C for 7 minutes was used.  
In other hand,  the PCR to identify and differentiate genotypes was carried out in 
50 µl of reaction contained a final concentration of 1X QIAGEN Master mix (10 mM 
of tris-HCl,  KCl, (NH
4
)
2
SO
4
 , pH 8.7), 200 µM of each dNTP, 2.5 U of QIAGEN Taq 
DNA Polymerase, 75 pM of  each primer (B3/B4 and B5/B6 respectively) and 3mM 
of MgCl
2. 
Different quantities of the RT products (1, 2 and 3 µl) of each viral strain 
were tested. The amplification program was run with a Hybaid PCR Express  
thermocycler and the amplification program was carried out for 5 minutes at 95°C for 
an initial denaturation and then submitted to 35 cycles of 94°C for 1 minute, 51°C for 
1 minute and 72°C for 1 minute. Additionally, a 55°C annealing temperature was 
tested. A final extension step of 72°C for 7 minutes was applied. With the aim to 
reduce the time in each reaction and in order to reduce the costs, a short protocol of 
time (30 seconds instead of 1minute of each step) and the use of 25µl instead of 
50µl  of total volume of reaction were tested in both PCRs.   
 
ELECTROPHORESIS. The amplification products were visualized by 
electrophoresis. Briefly, agarose (QA-Agarose TM, Qbiogene)  was melted in Buffer 
TAE 1X  (10X TAE, Shelton Scientific) in a final concentration of 1.5%.  Once that 
liquid agar was cooled enough, 10µl of etidium bromide (SIGMA, 10 mg/ml solution) 
were added and was poured into prepared casting tray. Ten microlitres of each PCR 
products were loaded with 2 µl of 1X Bromophenol Blue (Promega B.B Loading 
Solution)  into the wells and finally, 5µl of 100 bp Ladder (RBC100bp Ladder DNA 
Marker 50 µg/500µl) were used in each run. The electrophoresis tray (Scie-Plas) 
was filled with Buffer TAE 1X and finally the electrophoresis was run at 100V / 100 
mA  for 40 minutes. Gels were analyzed using a Gel logic 100 imagining system 
(KODAK). 
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                 III. RESULTS 
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1. Antibody and Antigen Detection 
 
The results obtained in the serological survey carried out in Central Italy showed 
a seroprevalence of 26.43% (469/1774) in unvaccinated farms, meanwhile 73.56% 
(1305/1774) was observed in vaccinated farms. BVDV seroprevalences of each 
region in unvaccinated farms were: Umbria: 20.35% (127/624), Marche: 24.92% 
(82/329) and Lazio: 31.66% (260/821) (Table 9). In other hand, from the vaccinated 
farm (Umbria) was obtained a general positivity of 81.29% (126/155), meanwhile 
18.70% (29/155) of animals were negative. In the base of group of age, 5.33% 
(25/469) of  animals younger than 24 month old and 85.28% (444/469) older than 24 
months old were positive (Table 10).   
In order to identify PI animals (seronegative / viremic animals), from a total 
number of 490 animals tested using the serum/ACE, a negativity of 100% was 
observed.   
 
Table 9. General results about BVDV Antibody and Antigen detection in the total number of animals and by 
region 
Antibody BVDV Serum/ACE 
No. Farms Region Vaccination 
No. of 
animals 
+ - + - 
10 Lazio No 821 260 561* 0 244 
6 Umbria No 624 127 497* 0 132 
4 Marche No 329 82 247* 0 85 
20 TOTAL  1774 469 1305 0 461 
  
 
 
    
1 Umbria Yes 155 126 29 0 29 
21 TOTAL  1929 595 1334 0 490 
*From all negative animals were selected only animals younger than 2 years old for being tested with 
serum/ACE   
 
On the basis of serological results, unvaccinated herds were divided in 3 groups: 
seronegative herds, seropositive herds with no recent cases of BVDV infection and 
positive herds with recent BVDV infections (Table 11). The criteria to differentiate 
between recent and not recent infection was the consideration of the presence of 
seropositive animals younger and older than 24 months old respectively (Ferrari G. 
et al., 1999). 
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      Table 10. Serological and antigen detection results from animals tested according to age. 
Antibody BVDV Serum/ACE 
< 24 m > 24 m < 24 m 
Region Vaccination 
No. of 
animals 
+ - + - + - 
Lazio No 821 25 244 235 317 0 244 
Umbria No 624 0 132 127 365 0 132 
Marche No 329 0 85 82 162 0 85 
TOTAL  1774 25 461 444 844 0  
Umbria Yes 155 1 29 125 0 0 29 
TOTAL  1929 26 490 569 844 0 490 
 
                        
2. Modifications of Serum/ACE 
Due to the negative results obtained from the identification of PI animals using 
the Serum/ACE, a modification in the incubation time was carried out (Kuhne S. et 
al., 2005). When overnight protocol at 4°C was used instead of 37°C for 2 hours, no 
differences were observed in the results. As additional research, 10-fold serial 
dilutions of TMV-2 (BVDV-2) strain infected-cells culture in BVDV antibody negative 
serum were tested. Positivity (OD> 0.3) was observed in a 10-3 dilution of BVDV 
strain (Graphic 1).  
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Graphic 1. Optical Densities obtained in serum/ACE using 
TMV-2 strain 10-fold serial dilutons   
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Table 11. Serological and antigen detection results in unvaccinated farms according to the  recent and no recent 
infections classification 
 
Herd status 
No. of 
Herds 
No. of  
animals tested Ab positive (%) PI animals 
Seronegative herd 1(5%) 60 0 (0%) 0 
Seropositive herd with 
no recent BVDV 
infection 
17 (85%) 1645 324 (19.69%) 0 
Seropositive herd with 
BVDV recent infection 2 (10%) 224 145 (64.73%) 0 
TOTAL 20 1929 469 (26.43%) 0 
 
 
3. RT-PCR 
Total RNA extracted from infected cell cultures was submitted to RT-PCR by 
using the B
E
B
2
 Pestivirus-specific primers, following the author’ s recommendations 
(Leteiller C., et al., 1999). An amplification product of the expected size (287 bp) was 
amplified from BVDV positive controls strains NADL, TMV-2 (a) and (b), and  BVDV-
2 (Fig. 9). For the RT and cDNA amplification, 2µl of  RNA and cDNA of each viral 
strain showed a better results instead of 1 or 3 µl. The bands with a  higher definition 
were those obtained from the RNA extracted from 100µl than those extracted from 
200µl of cell cultures. The expected amplification products were observed in all 
different annealing temperatures (data not shown). Several unspecific bands were 
observed in all reactions (Fig. 9), even using different annealing temperatures. For 
this reason, the  reduction of final MgCl
2
 concentration of 1.5mM instead of 3 mM 
was realized. Finally, all reaction were carried out using the annealing temperature 
of  57°C as previously recommended. After this modification, a specific band of  
287bp was observed without unspecific reactions. A final modifications about “ short 
protocol” and 25µl of final volume were carried out, obtaining optimal results 
(Fig.10). Thus, the optimal RT-PCR protocol was using 2µl of RNA and cDNA of 
each strain for retrotranscription and amplification, a final MgCl
2
 concentration of 
1.5mM and an annealing temperature of  57°C, using the short protocol in 25µl of 
final volume.  
The cDNAs from the four control strains were amplified with BVDV type I and 
type II-specific primer pairs B
3
B
4
 and B
5
B
6 
respectively (Fig. 11 and 12). A fragment 
of 221 bp was obtained in strain NADL using B
3
B
4
 primers and from TMV-2(a) and 
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(b) and BVDV-2 using the B
5
B
6 
primers, using the annealing temperature 
recommended of 51°C. No amplification product were obtained using the B
3
B
4 
primers
 
in genotype 2 strains
 
and
 
B
5
B
6 
primers in BVDV genotype 1 strains, 
corroborating their  specificity (Fig. 12). When we used the annealing temperature of 
55°C, unspecific bands were observed, deciding to remain with the original 
temperature. The final concentration of MgCl
2
 was 3 mM. Successful results were 
obtained using the short  protocol and 25µl of final volume of the reaction. On the 
basis of these observations, the optimal RT-PCR protocol was using 2µl of RNA and 
cDNA of each strain for retrotranscription and amplification, a final MgCl
2
 
concentration of 3mM and an annealing temperature of 51°C, using the short 
protocol in 25µl of final volume.  
In addition, no differences were observed between the amplification products of 
infected-cell cultures used as positive controls whith and without  previous RNA 
extraction method. In both cases, amplification of the expected band always was 
observed (data not shown). All sera pooled samples tested with PCR were negative. 
In each RT-PCR was used a positive control in order to validate the PCR .  
 
 
 9          10  
 
 
 
Fig. 9 and 10. Agarose gel 1.5% stained with ethidium bromide. Amplification products of B
E
B
2
 Pestivirus 
PCR. Fig. 9.  Lane 1. Ladder 100 bp; Line 2-5: Amplification products of 287 bp of strains: 2)NADL; 3) TMV-2 (a);  
4) TMV2 (b); 5) BVDV-2 using a concentration of 3 mM of MgCl
2
.  Fig. 10. Amplification products of B
E
B
2
 
Pestivirus PCR using short protocol, 1.5mM MgCl
2
 and 25 µl of total volume. Lane 1: Ladder 100 bp;  Line 2-5: 
Amplification products of 287 bp of strains: 2)NADL; 3) TMV-2 (a);  4) TMV2 (b); 5) BVDV-2.  
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Fig. 11 and 12. Agarose gel 1.5% stained with ethidium bromide. Amplification products of B
3
B
4 
(BVDV-1) 
and B
5
B
6  
(BVDV-2) PCR. Fig. 11. Lane 1: Ladder 100 bp; Line 2: Amplification product of Pestivirus (287bp) 
of NADL.  Line 3 and 4: amplification products of 221 bp using  primers B
3
B
4 
(BVDV-1) in NADL strain with 
51°C of annealing temperature; Lane 4: annealing temperature of 55°C.  Fig. 12.  Lane 1: Ladder 100 bp; Lane 2 
and 3: Amplification products of B
5
B
6 
(BVDV-2) in strains TMV-2 (a) and BVDV-2 using a concentration of 3mM 
of MgCl
2
; Line 4: NADL (BVDV-1) strain tested with B
5
B
6 
(BVDV-2) primers.  
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   IV. SECOND  EXPERIMENTAL  PHASE  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 66 
1. INTRODUCTION 
From April 2th to May 27 of 2008, Aurora attended a short stage at the Veterinary 
Diagnostic Laboratory at Rocky Ford (a Branch of the Colorado State University 
Veterinary Diagnostic Laboratory System), under the supervision of Dr. James 
Kennedy. The activities that she carried out were: 
1. Attendance of multiple seminars in regard to beef cattle health, production, 
infectious diseases, and their diagnosis at the “ Spring 2008 Academy of Veterinary 
Consultants Conference” ,in Omaha, Nebraska from April 3th to April 5th. From April 
7 to April 10, she attended a graduate level course on beef production that included 
topics on nutrition, economics of production, epidemiology, and record systems.  
During the same time frame she was afforded the opportunity to tour the United 
States Department of Agriculture Meat Animal Research Center where over 4,000 
beef cows are used for research in genetics and production. 
 2. From May 7 to May 10, she visited multiple feedlots in the southeast part of 
Colorado in collaboration with Pfizer Laboratories, with the objective to learn and 
understand several practices about management and production in beef cows. 
Additionally, on May 22, she participated in the ear notches sampling procedure in a 
feedlot with a previous BVD history. The following day, Aurora observed and 
participated in the gathering and processing of over 300 calves in preparation for 
summer grazing. 
3. The rest of the time, she observed and participated in several activities at 
the Veterinary Diagnostic Laboratory at Rocky Ford. Those activities included 
Bovine Viral Diarrhea (BVD) diagnosis, components of a Colorado’ s Voluntary 
BVD Control Program, the organization and pooling procedure of ear notches 
samples, RNA extraction, BVD viral detection using a specific Polymerase Chain 
Reaction (PCR), and the use of Antigen Capture ELISA on ear-notches surnatants  
to detect BVD virus.   
 
VETERINARY DIAGNOSTIC LABORATORY 
COLORADO STATE UNIVERSITY 
Colorado Voluntary BVD Control program 
 
The Diagnostic Laboratory at Rocky Ford has implemented a screening test to 
detect BVDV PI animals (Fig. 13). They have been used it for over two years and it 
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appears to have great potential as a herd screening tool. Five other States of 
America are also implementing similar efforts and the laboratories in those States 
are preparing to offer this type of test. Until current days, the Rocky Ford Laboratory 
had run over 40,000 samples on this  system. 
To achieve the objective, ear notches samples are used. The skin must be 
placed in a red top tube, and if not submitted fresh, it should be frozen until ready to 
submit. A small amount of a buffered solution is placed in the tube to immerse the 
skin sample, and then, an amount of the fluid is removed and combined with other 
samples up to a maximum of 100 samples. A PCR test is performed on this 
combined sample for BVD along with a positive control, in order to discard any kind 
of inhibition. The fee is $50 per pooled test plus other small fees, so if all the 
samples are negative,  the test would only cost $0.61 per head.  However, if the test 
is positive, further testing is needed to identify the PI animals. The test used for this 
propose is the ACE  and it costs about  $5 per sample.   
Statistical evaluation of RT-PCR to detect BVDV in pooled samples has shown a 
sensitivity and specificity of 100% and 97.35% respectively. The correct 
classification rate has been described of 97.7% with a Predictive Value of Positive 
and Negative Test of 85.1% and 100% respectively. This same test, has shown a 
correlation of 100% with IHC and ACE tests (Kennedy JA., 2006 a and 2006b).    
In order to collect the information from each farm, the farmers must submit a 
questionnaire to the Laboraratory prior to start the program. Information as  
pregnancy and weaning rates, mortality in calves, vaccination, percentage of 
abortions, open days, previous history of BVDV, movement / introduction of animals, 
presence of respiratory disease and knowledge about BVDV are required 
(http://www.dlab.colostate.edu/BVDControlProgram/bvdcontrolprog_main.cfm).   
 
2. METHODOLOGY 
      EAR NOTCHES SAMPLES.Using a commercial ear-notcher (Agrihealth Ear 
Notcher Pattern A V-shape), triangular ear notches (~2 cm) were obtained from a 
clean portion of  the ear (Fig 14 and 15). It was important to disinfect the ear-notcher 
before collecting next sample using a 10% bleach solution and rinsed with fresh 
water to remove the bleach.The procedure was carried out wearing gloves. 
Carefully, each sample was taken with a clean and disinfected clamp to be collected 
into a sterile red top tube without touching it during the management (Fig 16). 
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Samples were sent immediately to the Laboratory using a cold package for the 
transportation.  
                            Fig. 13. BVDV Control Program Flowchart 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
    
 
 
 
 
 
 
 
 
 
                                                                               
                                                                                        
 
 
 
 
 
 
 
 
POOLING SAMPLES PROCEDURE. The work area was wiped down with 
ELIMINase  prior starting, between each pool and when finished. Red top tubes with 
ear notches were arranged in 100-tube box and then the caps were removed.  A 
LABmax  dispenser was used to add 1 ml of PBS 1X to each tube, and then the 
BVDV Questionare Score Questionare 
Develop BVDV 
Biosecurity Program 
Ear notch all calves for 
pooled PCR 
Positive Pool No Positive pool 
Test ear notches from 
positive pools and the 
dams of positive 
calves 
Remove positive 
animals 
Test all cattle not 
previously represented 
by PCR pools or ear 
notches and remove 
all positive animals 
Certified Free herd 
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boxes were covered  using a plastic bag to let them stand for at least 10 minutes at 
4°C. After 10 minutes of incubation, samples were vortexed and using a sterile 
graduated transfer pipette, 250µl of ear notch fluid from each sample tube were 
recollected into a 50 ml Falcon tube labeled to form a pool (Fig. 17). Pool size never 
was greater than 100 samples. When pooling was completed, Falcon tubes were 
mixed by inversion gently and refrigerated at 4°C for at least 1 hour before RNA 
extraction.   
 
RNA EXTRACTION OF POOLS. Using the disposable pipettes, 350µl of each 
pool sample were collected for the RNA extraction. This procedure was carried out 
using the commercial kit QIAamp RNA Blood Mini Kit  following the manufacturer’ s 
instructions. Briefly, the samples were disrupt and homogenized with buffer RTL. 
The lysate (RTL/sample mixture) was pipette into a purple QIAshredder Mini Spin 
Column and centrifuged to discard the flow-through. Then, a volume of ethanol at 
70% was added and the homogenized was transferred to a  labeled QIAamp Mini 
Spin Column  included in the kit for being centrifuged to discard the flow-through. 
After adding RW1 buffer, which create the conditions that promote selective binding 
of RNA to the membrane, the samples were centrifuged again. Two steps of 
washing with Buffer RPE were realized followed by centrifugation. Finally, RNA was 
diluted in 30µl of Rnase-free water included in the kit and was used immediately. 
 
PRIMERS.The selected primers SBA-F5-GTAGTCGTCAGTGGTTCG-3 and 
SBA-R 5-GCCATGTACAGCAGAGAT-3 were used to amplify a product  of 145 bp of 
the high conserved  5’ UTR of the BVDV 1 and 2 genotypes(Ridpath JF., et al., 
1994).  
 
cDNA SYNTHESIS AND PCR. In order to detect PCR inhibitions, a duplicate 
template for each sample was spiked with BVDV viral RNA for a final concentration 
of at least 10 and no more than 100 viral particles per ml. The BVDV positive control 
should be at a concentration of 1000 to 10,000 viral particles per ml.  At the same 
time, a positive control was always run in each PCR reaction.  
For the cDNA synthesis, the first step was to prepare the template mix formed by 
4.75µl of RNA and 0.5µl of each primer (Promega, 50µM). The mix was heated at  
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70°C for 10 minutes in the thermocycler  (Techne TC-412 Thermal Cycler) and 
then cooled on ice for 10 minutes. Then, the samples were placed in a frozen rack in 
a -70°C freezer for 10 or 15 minutes. The second step was to prepare 4.75 µl / 
sample of RT-Mix adding 2µl of 5X buffer (Promega, 250 mM KCl, 250mM Tris HCl 
Ph 8.3, 50 mM MgCl
2
), 1µl dNTPs (10 mM/each), RNAsin 0.25µl (Promega, 10 
Units), 5U of AMV RT(0.5µl) (Promega Reverse Transcriptase) and 1µl of NaPP. 
Once prepared, 4.75µl of RT-Mix were added to each frozen template (4.75µl), 
pipetting to the bottom of the tube through the mineral oil and expelling next to ice 
cube. Samples were incubated at 45°C for 1 hour using the thermocycler.  
 
To prepare PCR Master Mix, in a total volume of 35µl were added 21µl of water, 
4.5µl of 10X Buffer, 1.5µl of MgCl
2
 (50mM), 1µl of dNTPs, 1µl of each primer SBA/B-
F and 5 µl of 1% Triton-X. This mix was added to each reaction tube and put in the 
thermocycler to denature at 99°C for 4 minutes. After this incubation, tubes were 
hold in thermocycler  at 90°C while 5µl of Taq (Bioline Taq Polymerase) was added 
to each tube, obtaining a total volume of 50µl.  Finally the amplification program was 
run at 95°C for 1 minute, 55°C for 1 minute and 72°C for 2 minutes. A final extension 
step of 72°C for 5 minutes was carried out.  
 
ELECTROFORESIS. The amplification products were visualized by 
electrophoresis. For that propose, 5 gm of agarose (GenePure LE Agarose)  were 
melted in 140 ml of 0.5X TBE buffer (5X TBE Buffer). Once that liquid agar  was 
cooled enough, 15µl of Etidium Bromide (10 mg/ml solution) were added and was 
poured carefully  into prepared casting tray. A pipette tip was used to move any 
bubbles away from the teeth of the combs to the edge of tray. Twenty microlitres of 
each PCR product were mixed with 1µl of the Loading Dye Solution (Promega 
Bromophenol Blue Loading Solution) into the wells,  and 5µl of 100 bp Ladder (New 
England BioLabs 100bp DNA Ladder) were used in each test. The electrophoresis 
tray was filled with 0.5X TBE Buffer. The electrophoresis was run at 80V for 1 hour 
and gels were analyzed using a transilluminator.  
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 14       15 
 
Fig. 14 and 15. (Left) Ear from a PI animal. (Right) Ear notcher and clamps used for sampling 
procedure. 
 
                           16      17  
 
Fig. 16 and 17. (Left) Ear notch collected in a sterile red top tube. (Right) Pooled samples from 50 ear 
notches surnatants. 
 
INTERPRETATION OF PCR RESULTS. Ladder and BVDV positive control 
bands were used to classify the tested pools  bands as “ BVDV not detected”  or 
as “ Positive”  if a band of 145 bp was observed. A positive BVDV band always 
had to be present in spiked samples. If not, a result of “ PCR inhibition” was given.   
There were three possible outcomes for PCR results. “ BVDV not detected” is self-
explanatory. A result stating “ Positive” means that virus was identified in the pool 
but may be the result of the presence of a PI animal or in some occasions, an 
acutely infected animal (less than 2% of pools have been identified and no positive 
animals found). The third possible outcome was “ PCR inhibition” and this result 
occurred when some foreign substance contaminates the sample (less than 4% of 
pools show inhibition). Whenever the virus is detected or when pools show inhibition, 
individual samples are automatically evaluated.  
  
 
 
 
 72 
BVDV ANTIGEN CAPTURE ELISA TEST 
The commercial test BVDV Antigen Test Kit  (HerdCheck IDEXX, USA) was used 
to test individually the ear notches surnatants from positive pools. The kit is based 
on the detection of structural glycoprotein Erns of BVDV through the use of 
monoclonal antibodies (MAbs) and was carried out  following the manufacturer’ s 
instructions. Briefly, micro-wells were washed with washing solution before starting. 
Ear-notches surnatants were incubated at room temperature (RT) for one hour and 
after were washed away to eliminate the unbound material. A working detector 
reagent was added  and incubated for 1 hour at RT and washed away. After this 
incubation, captured antigen was detected by specific antibodies and horseradish-
peroxidase conjugate. Then, unbound conjugate was washed away and 
substrate/chromogen solution was added. In the presence of enzyme, substrate is 
converted into a product that reacts with the chromogen to generate a blue color. 
Upon addition of the stop solution, a yellow color is generated. The optical density 
(OD) of the plate was measured using a spectrophotometer (Emax Miroplate 
Reader) at a single wavelength of 450 nm .  
 An OD <0.2 was catalogued as negative, between 0.2-0.39 as suspect and 
>0.39 as positive. A positive BVDV ACE test may not be indicative of PI animals. A 
positive result on a second test at least 3 weeks after the initial sample can confirm a 
PI animal. Suspected animals resulting for the ACE were retested twice, first using 
the standard working detector regent (monoclonal goat anti-BVDV antibody) and 
then using a “ modified”  working detector (containing no detector antibody) with 
the aim to obtain a ratio between optical densities. 
 
3. GENERAL RESULTS 
In a period from April 5th to May 26 of 2008, a total number of 14,508 ear 
notches samples were received in the Laboratory. The samples were originally  from 
Colorado state, but also from others states of America as Nebraska and New 
Mexico. From these samples, a total of 360 pools of an average number of 40 
samples were tested. From these pools, 28 were positive to RT-PCR and when 
samples were tested individually using the ACE, 15 animals were catalogued as 
positives. All positive animals in ACE were retested 3 weeks later and confirmed as  
PI animals. Positive animals were Hereford breeding with an average age of  4 
months.    
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       V. DISCUSSION  AND CONCLUSIONS 
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In Italy, little research has been done concerning  about BVDV seroprevalence 
and at this time no compulsory/voluntary control program exists in order to detect 
and eliminate PI animals. For that reason, the study of seroprevalence in Central 
Italy was an  important  research to understand the BVDV epidemiology in this area. 
The serological investigation was realized using a commercial ELISA that has shown 
a high sensitivity and specificity of 99.5% under field infections. Also it has 
demonstrated a strong association of 96.3% with the Virus Neutralization Test, 
which is considered as the golden standard of the serology in BVDV infections 
(Solis-Calderon JJ. et al., 2005). The serological survey carried out in unvaccinated 
herds in Central Italy showed a relative BVDV seroprevalence of 26.43%, meanwhile 
the seroprevalence obtained by regions were 20.35%, 24.92% and 31.66% in 
Umbria, Marche and Lazio respectively. These results demonstrate the presence of  
BVDV infection in a low prevalence and in general reveal that the situation in Central 
Italy is not critical about BVDV compared with  others regions or countries, where 
BVDV is endemic reaching seroprevalences up to 90% (Greiser-Wilke I., et al., 
2003; Moennig V., et al., 2006; Lindberg A., et al., 2005). 
In a previous survey on bulk milk samples of 379 dairy herds in the Umbria 
region in Central Italy, antibodies were demonstrated in 45 samples, resulting in a 
prevalence at herd level of 11.8% (Luzzago C.,et al., 2001). In other research, a 
seroprevalence of 53.3% in 29 unvaccinated farms in northern Italy using the serum 
neutralising test has been reported (Luzzago C. et al.,1999). In other hand, a 
seroprevalence at individual level of 31.4% was reported in Rome province (Ferrari 
G. et al., 1999) using a competitive ELISA test.  Only one research has shown a pick 
of seroprevalence of 91% in northern Italy during a period of ten years, but the study 
did not  differentiate between non-vaccinated and vaccinated herds (Cavirani  S. et 
al., 1992).  
In other hand, it is important to refer that in Italy there are important differences in 
density, size and management between North Italian and Central Italian herds. In 
general, North Italian herds are more numerous and the animal-to-animal contact is 
closer, resulting in higher risk of viral transmission and consequently in higher 
seroprevalences (Lindberg A. and Houe H., 2005; Ezzano P., et al.,2008). It was 
shown that the herds with high cattle population density had higher prevalence of 
infection than the herds which were smaller (Houe H., et al., 2006; Hult L., et al., 
2005). For that reason, the seroprevalences obtained in Central Italy regions could 
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be lower than those observed in other regions due to the different herd size and 
management system.  
The results obtained about seroprevalence acording to the group of age showed 
the tendency of a higher risk among older (>2 years old) animals compared to 
younger (aged <2 years) animals. This phenomena  has been previously reported 
(Mockeliū niene V., et al., 2004; Garoussi  MT., et al., 2008) and it has been 
demonstrated that animal age has an important influence on the prevalence of 
BVDV infection. Some reports have shown that in the third and consecutive years of 
life, the number of seropositive animals increases reaching its maximum in the age 
groups of 5 and 7 years. The increase in antibody prevalence by increasing age is 
probably due to the higher exposition  to the antigens and that BVDV antibodies in 
most cases are lifelong (Mockeliū niene V., et  al., 2004). 
On the basis of serological screening, herds were classified with and without 
recent cases of infection. Five percent of farms were seronegative, 85% were 
seropositive with no recent BVDV infection and only 10% had a recent or on-going 
infection. Previous researches carried out in different parts of Italy have shown that 
the seroprevalence in the presence of recent infections within farms involved and in 
the absence of a systematic control program were of 8.8% (Ferrari G. et al., 1999) 
and 33.8% (Luzzago C. et al., 2008) respectively. In this way, we can consider that 
the percentage of recent infected farms observed in our research is similar to that 
reported in herds that are participating in a systematic control, where PI animlas are 
constantly eliminated. The possibility of external sources of infection in seropositive 
farms with recent infections must be considered.  
In other hand, in vaccinated herds was obtained 73.56% of positivity due to the 
post-vaccination immune response mounted by animals, meanwhile the general 
negative percentage was 26.44%. It is possible that the reason why some animals 
are not developing a post-vaccination immune response could be for the failure in 
vaccine application and/or conservation (4°C), mistakes in animal’ s control during 
the vaccination (missed animals during vaccination), an incomplete protection 
against BVDV infection due to immunosuppression for the possible presence of 
other infectious agents as Bovine Immunodeficiency Virus (Zhang S., et al., 1997) 
and the use of inactivated vaccines that generally produce a weaker last-long 
immune response (Potgieter LN., 1995; Platt R., et al., 2008), adding to this situation 
the possible lack or failure in booster vaccination.  
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In Italy, the presence of BVDV PI animals has been reported previously, 
principally in the northern part of the country (Falcone E., et al., 2001; Piccinini R., et 
al., 2006; Luzzago C., et al., 1999, 2001 and 2006), where the presence of an 
unusual number of PI animals suffering MD in one of more farms has been reported, 
phylogenetically related to BVDV genotype 1 (Ciulli S., et al., 2008). One of the 
principal objectives of this research was to identify PI animals within sampled farms 
in order to evaluate the use of different diagnostic tools for their identification. For 
that propose, young animals (<2 years old) were tested, based on previously reports 
that show that PI cattle die during the first years of life (Tautz N.,et al., 1998; 
Potgieter LN., 1995; Smith DR. et al., 2004).  
In our study, from 490 young animals tested, a negativity of 100% was obtained 
in BVDV antigen detection, even if overnight incubation method was used with the 
intent to improve the sensitivity of the test (Kuhne S. et al., 2005). Technical causes 
have been excluded when 10-fold serial dilutions of BVDV TMV-2 strain were tested 
with optimal results, thus it was possible to corroborate that viremic and PI animals  
were not  detected. For the antigen detection only serum samples were used, and 
although some authors recommend its use to detect the BVDV antigen with good 
results compared with other tests (Saliki JT., et al., 2000; Kuhne S. et al., 2005; 
Kampa J. et al., 2007; Hill FI., et al., 2007), other authors express their doubts about 
the ability of the test on sera samples to detect PI animals (Grooms DL. et al., 2002; 
Gripshover EM., et al., 2007). However, test has been validated by the manufacturer 
for using sera samples, adding that are easy to collect and are most frequently sent 
to the laboratories for BVDV diagnosis.  
The Serum/ACE used for this research is based on monoclonal antibodies to 
capture the Erns BVDV antigen, which is thought to be highly conserved among 
BVDV strains (Bolin SR., et al., 2004; Vilcek S., et al., 2005). According to the 
manufacturer, this test has shown a sensitivity and specificity of 91% and 97% 
respectively in field infections. Application in control programs of the Serum/ACE for 
the detection of PI animals has shown good results and agreement with other 
commercial kits as well as IHC, RT-PCR and indirect immunoperoxidase tests 
(Cornish TE., et al., 2005; Kennedy JA., et al., 2006 a and 2006b; Hilbe M., et al., 
2007). Serum/ACE is used successfully in countries that have started a BVDV 
control programm as Netherlands, where blood pooled samples are tested first by 
RT-PCR and from the positive pools, the animals are tested individually with the kit 
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(Mars MH., et al., 2005). Controversially, Gripshover EM., et al, (2007) demonstrated 
that there is a unique mutation in the portion of the genome coding for the Erns 
glycoprotein envelope associated with failure of IHC and ACE assays to detect some 
field strains previously detected by virus isolation and PCR testing from PI animals. 
Concerning about the RT-PCR standardized, it was considered as specific to the 
high conserved region of the 5’ UTR, and have been used by other authors with 
high sensitivity and specificity (Leteiller C., et al., 1999 and 2003; Groom J. et al., 
2001; Luzzago C. et al., 2001;Toplak I. et al., 2004). The fact that RNA from all cell-
infected cultures tested showed a better integrity using 100µl of initial material than 
200µl could be due for the high quantity of RNA of the samples which exceeds the 
capacity of RNA binding to the Rneasy membrane, reducing the RNA yields. About 
the PCR to detect Pestivirus, the MgCl
2
 concentration of 3mM had an important 
influence in unspecific reactions and when the final concentration of 1.5 mM was 
used, it was possible to eliminate the unspecific bands. The expected amplification 
products were obtained from all different strains. About the PCR to identify and 
differentiate between BVDV genotypes, no cross-reactivity was detected between 
type-specific primers. In both PCRs, the use of short protocol and the reduction of  
25 µl  instead  of 50µl of the total volume considerably reduced the cost and the time 
to carry out each reaction.  
No differences were observed between the amplification products of BVDV 
infected-cell cultures used as positive controls with and without previous RNA 
extraction method. This phenomena has been described before, using samples as 
blood, buffy coat and serum. These results consent to conclude that RNA extraction 
can be omitted without loosing sensitivity of virus RNA detection (Groom J., et al., 
1999; Ridhpath JF., et al., 2002; Deregt D., et al., 2002), and decreasing at the 
same time the economical costs of the diagnosis.    
With the aim to develop an economical diagnostic test for the screening PI cattle, 
a RT-PCR assay in pooled sera samples was used in this research. It is important to 
consider the optimal size for pooled sera lots that depends on herd size and the 
ages of the cows to be tested. Sera from older multiparous cows with a lower 
prevalence of PI can be pooled into larger lots of sera samples than sera from 
animals of 2 years old or less, which have a higher expected prevalence of BVDV 
infection (Weinstock D., et al, 2001). For this reason, in this research only animals 
younger than 2 years old were tested in order to increase the possibility to detect PI 
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cattle. Some works have reported that  serum may have lower amounts of virus 
compared with other samples as blood or buffy coat, recommending that pools 
formed must to be maximum of 10 samples (Muñoz-Zanzi CA., et al., 2000; Daly R., 
et al., 2006). Following this recommendations, sera pools for this research were 
formed by 5 samples in order to avoid the decrease of  sensitivity using RT-PCR.  
Previous reports have shown that a single PI animal can be detected in pools of 
30 (Smith RL.,et al., 2008) and until 100 sera samples (Weinstock D., et al., 2001). 
Additionally, high antibody titers in pooled sera samples had no appreciable effect 
on the sensitivity of detection of BVDV by RT-PCR and the rate of degradation of the 
viral RNA and the stability of BVDV in serum depends on the initial virus titer, 
sample handling, and the purity of the serum (Weinstock D., et al., 2001). These 
studies estimate the diagnostic sensitivity of RT-PCR for BVDV and confirms that it 
is a useful diagnostic tool for sera pools screenings. Our results have showed that all 
tested pools were negative using a highly sensitive RT-PCR (Luzzago C. et al., 
2001;Toplak I. et al., 2004), presuming that the results obtained were truly negative.  
 Several factors must be considered concerning about the negative results. One 
of the most important is the low prevalence of PI animals, ranging from 0.5 to 2% 
(Brock KV., 2003; Greiser-Wilke I., et al., 2003; Niskanen R., et al., 2003; Moennig 
V., et al., 2006). In other hand, It has been observed that a low percentage of PI 
animals do not present detectable titers of viremia due to the antibody production 
against some homologous BVD virus spontaneously mutated, representing the 
“ incomplete immunotolerance” theory (Fray MD., et al., 2000). In the same way, 
some researches have reported the intermittence and variation of viremia 
simultaneously with its declination with the time, specifically after 2 years old of age 
(Brook KV., et al., 1998; Fray MD., et al., 1998 and 2000; Baule C., et al., 2001; 
Grooms DL., et al., 2001). These phenomena could explain some missing periods of  
viremia that could be important contributors in the inefficient detection of PI animals.   
PI animals are considered  the principal source of infection in a farm and within 
herds, and direct contact between these animals and susceptible ones is the most 
important route of infection (Houe H., 1999; Greiser-Wilke I. et al., 2003; Smith DR., 
et al., 2004; Lindberg A., et al., 2005). In this work, the presence of BVDV infection 
has been corroborated in a low percentage in the absence of PI animals. In addition, 
10% (2/20) of the total farms samples are presenting on-going infections. Some 
works have reported the transmission of the disease within herds even if the 
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absence of PI cattle, guessing the important role of the transient infected (TI) 
animals that can spread the virus for long periods of time (Moerman A. et al., 1993; 
Moen A. et al., 2005;). In the same way, a case of severe course of a primary BVD 
infection in a seronegative herd after the introduction of  a transiently  infected (TI) 
calf was described (Sol J. et al., 1989).The probability of horizontal transmission 
during a contact with a TI animal stands in sharp contrast to that of PI animals, due 
to the intermittent shed of relatively low amounts of virus. In fact, there are 
experimental results that indicate that the primary infection may be only rarely 
propagated (Niskanen R.,  et al., 2003). Even this feature, the probability of vertical 
spread resulting from a TI animal is much higher than the probability of horizontal 
spread. In fact, most new PI detected in an infected herd will be the result of 
transient infections in dams with a normal immune response (Lindberg A. and Houe 
H., 2005).  
Nevertheless, external routes of infection must be considered as important ways 
of transmission, as the use of contaminated semen and embryos (Perry GH., 2007; 
Gard JA., et al., 2007), contaminated vaccines (Falcone E., et al., 1999; Barkema 
HW., et al., 2001), unhygienic treatment procedures and contaminated housing 
conditions (Niskanen R., et al., 2003; Ezzano P., et al., 2008) as well as airborne 
transmissions between animals (Mars MH.,  et al., 1999; Smith DR., et al., 2004). 
In other hand, it has been shown that the prevalence of seropositive animals in 
unvaccinated  herds with one or more PI animals generally is high, ranging from 
87% to 98% (Waldner CL., et al., 2005; Seki Y., et al.,  2006;Houe H., et al., 2006),  
contrary in those without PI animals ranging from 8 to 29% (Seki Y., et al., 2006)  
and reaching until 49% (Garoussi  MT., et al., 2008). Therefore, a high prevalence of 
seropositive animals is an indirect evidence of the presence of PI animals. This 
connection has been utilized as a means of making a preliminary herd diagnosis by 
testing a small herd sample for antibodies against BVDV in areas where BVDV 
vaccination is not available. In areas where vaccines are used, the problem is more 
complex, because it has to be determined whether the antibody titer is due to 
vaccination or due to exposure to a PI animal, but generally, the antibody titers in 
herds with PI animals are higher than those among cattle in herds without PI 
animals, even if the cattle in the herds had been vaccinated with a killed vaccine 
(Ståhl K., et al., 2008). However, some herds without recent BVDV exposure may 
have older animals with high titers, presumably resulting from a previous exposure 
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to a PI animal (Houe H., 1995; Ståhl K, et al., 2007). The seroprevalences obtained 
in this work were considered as low, and we can presume that are similar than those 
reported in BVDV seropositive farms without the presence of PI animals.  
Different surveys show considerable variation in the prevalence of PI animals 
as well as prevalence of antibody positive animals. Several differences in cattle 
population structure, cattle density, herd size,  housing systems, animal movement / 
introduction / purchase, bio-security practices and management in general could be 
important risk factors playing an important role in transmission and persistence of 
BVDV (Valle PS., et al., 1999; Wittum TE., et al., 2001; Sthal K., et al., 2007). For 
that reason, the low herd density in the central regions of Italy and the probable right  
management practices within herds must not be excluded as contributors and 
possible factors that could reduce the presence of PI animals. 
Finally, the use of contemporary sampling of different materials than serum in the 
same animal (Cornish TE. et al., 2005; Edmondson MA., et al., 2007;Hilbe M., et al., 
2007b), a serum re-sampling protocol with a difference of at last 30 days between 
samples (Grooms DL. et al., 2001 and 2002), the examination of white blood cells 
(Baule C. et al., 2001; Gogorza LM. et al., 2005) and ear notch samples (Kuhne S. 
et al., 2005) are practices that could increase the possibility to detect BVDV PI 
animals. The serum/ACE has shown a better results when ear notch samples are 
used (Kennedy JA., et al., 2006 a and b; Hill FI., et al., 2007),meanwhile the 
examination of white blood cells (buffy coat) with the ACE test is also recommended 
to detect BVDV antigen with a higher sensitivity (Baule C., et al., 2001; Cornish TE., 
et al., 2005; Gogorza LM., et al.,  2005).  
Recently, no compulsory BVDV control Program exists in Italy.In geographical 
areas where governments and organisations of  farmers do not consider BVDV to be 
a priority, control is dependent on voluntary measures. In Italy, the herd 
seroprevalence of BVDV ranges from 57% to 95% (Ferrari G. et al., 1999; Luzzago 
C., et al., 2008) and there is high BVDV genetic variability relative to other EU 
countries (Luzzago C.,et al., 2001). Despite this,a temporary compulsory program in 
Italy has been developed in the North-Eastern region (Luzzago C., et al., 2008) and  
in a voluntary way in Rome province for a short period of time (Ferrari G., et al., 
1999). Both programs were based on the identification and elimination of PI animals. 
According to our results, no PI were identified in the Central regions sampled, even 
the presence of BVDV infection. For that reason, and in the absence of national or 
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local controls, there is a need to quantify the risk of introduction and spread of BVDV 
in order to  increase the awareness of farmers in order to spread the right knowledge 
to prevent new infections that could increase the prevalence. At the same time, we 
strongly recommend the application of other diagnostic techniques such as IHC, RT-
PCR and ACE using buffy coat and/or ear notches samples to detect the presence 
of PI animals (Cornish TE. et al., 2005; Hilbe M., et  al., 2007; Hill FI., et  al., 2007). 
BVDV is a common disease of United States cattle herds (Larson RL., et al., 
2004 and 2005; Loneragan GH., et al., 2005). The disease affects producers and the 
livestock industry through increased treatment expenses, calf and pregnancy losses, 
and decreased weight gain (Gunn GJ., et al., 2004). During the short stage at the 
Veterinary Diagnostic Laboratory of the Colorado State University, a total number of 
14,508 ear notches samples were submitted to the Laboratory for testing for BVDV 
PI animals. All samples were obtained from farmers that were agree to participate in 
the voluntary program. Following the protocol of testing individually the samples 
derived from positive pools with ACE, a prevalence of 0.1% of PI was obtained. This 
prevalence has been described everywhere, ranging from 0.5 to 2% (Brock KV., 
2003 and 2006; Moennig V., et al., 2005a; Lindberg A., et al., 2006).Current 
practices in USA cattle industry do not limit the risk of exposure to PI animals. A 
recent feedlot study showed that 30.8% of 240 pens would contain at least 1 PI 
animal, given a prevalence of 0.4% PI animals and a total of 21,743 head (Ridpath 
JF., et al., 2006b).  
The dairy industry has used RT-PCR to successfully detect the presence of 
BVDV in bulk-tank milk samples, but that particular source is not available in beef 
cow operations. Screening ear notches by pooled RT-PCR could offer a low-cost 
and highly sensitive test to detect BVDV (Kennedy JA. et al., 2006 a and b). 
Screening ear notches with pooled RT-PCR followed by AC-ELISA with PBS 
solution to detect individual positive samples offers the potential for performing serial 
testing to minimize expense and laboratory time and could allow potential PI animals 
to be removed from the herd in less than 72 hours of laboratory time at a reasonable 
cost to the producer. In addition, RT-PCR used in this laboratory has shown to be 
highly sensitive, reaching a 100% on pooled samples when at least 1 positive animal 
to ACE is contained in a pool of 100 samples. Therefore this system of 100 animals 
provided a screening method that detect all the individual positive IHC and positive 
ACE samples (Muñoz-Zanzi CA., et al., 2000; Kennedy JA., et al., 2006a and b). 
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Increasing the pool size above 100 might result in a failure to detect the virus if the 
dilution were to become great enough. Conversely, decreasing the pool size could 
allow for more frequent detection of TI animals and a subsequent decrease in the 
number of times the pool was confirmed to contain a positive ACE.  
Important and different results were observed about the prevalence of PI animals 
between surveys carried out in Central Italy and in Colorado (USA), being 0% and 
0.1% respectively.Those differences could be due to the different number of animals 
sampled. This difference was important because in Colorado the voluntary program 
is well organized, the farmers are agree to participate and eliminate infected animals 
and the most important is that they are conscious about the importance and risk that 
BVDV means for their herds, so they participate constantly in the program. In other 
hand, in Italy there is no compulsory/voluntary program developed in the Central 
area, becoming difficult to convince the farmers to get involved.    
Another important point to discuss is the different samples used in each survey 
(serum vs. ear notch). In previous researches, using ear notches samples to detect 
PI animals with the ACE, it has been possible to identify until 100% of animals 
previously detected by VI and RT-PCR  (Edmondson MA., et al., 2007; Hill FI., et al., 
2007). Both sera and ear tissue samples from PI calves have been tested and while 
sera samples were negative in ACE after intake of colostrum, the ear tissue samples 
could be detected positive for BVDV all the time. In the same way, testing multiple 
samples derived from the same ear from PI cattle yielded positive results and low 
variation (Kuhne S., et al., 2005). Contrary, sera samples used for BVDV antigen 
detection have shown a wide variability in the results (Saliki JT., et al., 2000; Plavsic 
MZ., et al., 2001; Kuhne S., et al., 2005).    
Differences between management and herd practices are factors that must be 
considered. In beef herds, PI suckling calves are commonly in contact with the 
breeding herd during early gestation when the foetus is susceptible to BVDV 
persistent infection. As a result, PI suckling calves are considered to be the primary 
source infection and maintenance of BVDV within breeding herds. Efforts to 
eradicate PI animals in infected beef herds should therefore emphasize testing of 
calves prior to the beginning of the breeding season, with follow-up testing of dams 
of positive calves and animals without calves available for testing. The opposite 
situation could be observed in dairy cattle, where the calf-weaning is carry out 
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immediately or some hours after calving, decreasing the possible contact between 
newborn PI animals and  dams (Talafha AQ.,  et al., 2008; Ezanno P., et al, 2008).  
The importance and the role that wild animals as deer in the BVDV epidemiology 
in Colorado state must be considered. Previous researches have reported that even 
that the prevalence of BVDV PI in deers is low, some percentage of adult animals  
could be playing an important role in the transmission and maintenance of BVDV to 
bovine herds (Duncan C., et al., 2008). 
 Epidemiological investigations have shown that demographic factors such as 
herd size and herd density are significant predictors for the prevalence of infection in 
populations where BVDV is endemic (Valle PS., et al., 1999; Houe H.,1995 and 
2003; Brock KV., 2004b). It has been estimated that in an endemic area the 
maximum possible number of PI animals will be around 2% (Greiser-Wilke I., et al., 
2003). However, in a few regions, the infection is present at a much lower 
prevalence. Studies from the US indicate that BVD virus is present in relatively few 
herds, but occasionally in high numbers in these herds, revealing  several herds with 
multiple BVDV positive animals (Houe H., 2003). In America, the use of having 
animals on pasture as well as herd size and purchase intensity, are considered  
important  risk factors significantly associated with presence of PI animals in the 
herds. Contrary, In Central Italy, the current herd management practices and low 
cattle density may be contributors to the low presence of  PI animals. Thus, it seems  
that there are several and important  epidemiological differences between both 
studied regions.  
In conclusion, BVDV infection in bovine herds of Central Italy is not critical, but 
BVDV is present in all the farms included in the study. The absence of PI animals 
suggest that other routes of transmission need to be considred and investigated. A 
voluntary eradication program in Italy could improve the health status of the animals 
and reduce the economic losses. A diagnostic system like that one existent in 
Colorado could be easily developed, but the main problem to be solved is the 
consensus and participation of the farmers. Dissemination of information should be 
done at national level in order to explain to the farmers the advantages that they 
would have in eradicating BVDV infection in their farms and in order to involve them 
in the eradication program. 
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VII. Annex No. 1     (Page 1)                               
                                                         EPIDEMIOLOGICAL FORM 
 
1. GENERAL INFORMATION 
 
Reception date__________________________                                      Reg. num________ 
No. of samples received __________________ 
 
2. Samples 
 
       Serum          Plasma            Blood                 Tissue          Other: ______________ 
 
3. Name of the farm / Address / Telephone:________________________________________ 
 
4.Name of the Veterinarian / Address/ Telephone: __________________________________ 
 
5. Herd Size / Zootecnic function: ________________________________________________ 
 
6. Vaccination 
                      IBR          BVDV           PI3                Others: ______________________ 
 
              MLV           Inactivated          Polivalent             Monovalent         No vaccination 
 
 
Last  vaccination: ______________________________________________________________ 
 
Vaccination program: ___________________________________________________________ 
 
7. Clinical signs 
 
Clinical history of the farm: ______________________________________________________ 
 
% Abortion____________________________________________________________________ 
Reproductive disorders __________________________________________________________ 
Respiratory disorders ___________________________________________________________ 
Others _______________________________________________________________________ 
 
8. Have you had BVDV in your farm? _____________________________________________ 
 
9. Have some animals been introduced in the farm?  When? __________________________ 
 
10. Have you tested new animals to detect BVDV?___________________________________ 
 
11. There are farms near? (si / no / km) ____________________________________________ 
 
10. Post-mortem inspection 
Macroscopic/ histophatological  founds: _____________________________________________ 
 
11.Other information: __________________________________________________________ 
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GENERAL  INFROMATION  OF  ANIMALS (Page 2) 
 
   Age (months) Sex Origin Physiol. Status  
 
 ID Breed <24 >24 M/F B P P NP BVDV Ab 
BVDV 
Ag 
1            
2            
3            
4            
5            
6            
7            
8            
9            
10            
11            
12            
13            
14            
15            
16            
17            
18            
19            
20            
21            
22            
23            
24            
25            
26            
27            
28            
29            
30            
31            
32            
33            
34            
35            
36            
37            
38            
39            
40            
Origin: B:  born in the farm  P: purchased  
Physiologic status: P: pregnant   NP: no pregnant 
BVDV Ab: ELISA Antibody test 
BVDV Ag: ACE
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AURORA ROMERO TEJEDA 
ACADEMIC ACTIVITIES  
2006-2008 
 
From January of 2006 to December of 2008 
Activities:  
o Development of a research project  aimed at  the evaluation of diagnostic methods 
to detect Bovine Viral Diarrhea affected cattle.  
o Optimizing serological and PCR protocols to detect bacterial and viral pathogens 
responsible for infectious diseases of different animals.   
o Collaboration in a research group to develop works and their presentation in 
international congresses. 
o Collaboration as a member of the examination Commission for the “ Microbiology”  
and “ Animal Infectious diseases”  courses. 
Place: Infectious Diseases Laboratory.  Faculty of Veterinary Medicine,  University 
of Camerino.  
Responsible: DVM, Dr. Silvia Preziuso.  
 
From  April 2th to May 30 of 2008 
Activities: 
o To observe and participate in activities concerning the different diagnostic 
procedures and their applications to Bovine Viral Diarrhoea (BVD) control with 
special emphasis on the development of the Colorado Voluntary BVD Control 
program 
Place:  Veterinary Diagnostic Laboratory. Rocky Ford, Colorado (United States of 
America). 
Responsible: DVM, MS. James A. Kennedy. 
 
     Scientific Publication in International Congresses 
1. Cuteri V., Attili A.R, Cittadini F., Preziuso S., Romero Tejeda A., Marenzoni M.L, 
Valente C. Selected agents involved in Buffalo (Bubalus bubalis) abortion in central 
Italy. XIV Congreso Internacional de la Federación Mediterránea de Sanidad y 
Producción de Rumiantes (FEMESPRUM). From 12 to 15 of July of  2006, Lugo-
Santiago de Compostela, Spain. 
 113 
2. Cuteri V., Cittadini F., Romero Tejeda A., Preziuso S., Marenzoni M.L, 
Passamonti F., Attili A.R, Giorgi G., Valente C. Interaction between BVDV and 
BoHV-1 infection in dairy herds in Italy. XIV Congreso Internacional de la Federación 
Mediterránea de Sanidad y Producción de Rumiantes (FEMESPRUM). From 12 to 
15 of July of  2006, Lugo-Santiago de Compostela, Spain.  
 
3. Cuteri V., Romero  Tejeda A., Splendiani  F., Valente C., Preziuso S. PCR 
identification of the virulence plasmids of Rhodococcus equi isolated from horses in 
Italy. LXI Convegno Nazionale della Società Italiana delle Scienze Veterinarie 
(SISVET). Salsomaggiore Terme (PR), Italy.  September 26 to 29 of 2007.  
 
4. Romero Tejeda A., Thiry J., Preziuso S., Thiry E., Petralia P., Valente C., Cuteri 
V. Serological detection of a Bovine Herspevirus 1 related infection in buffaloes 
(Bubalus Bubalis) by using BoHV-1 Blocking ELISA. XVI Congress of the 
Mediterranean Federation for Health and production of Ruminants (FeMeSPrum), 
April 22-26 of 2008. Zadar, Croatia.  
 
5. Romero Tejeda A., Thiry J., Preziuso S., Thiry E., Cuteri V.  Bovine Herpesvirus 1 
Related Infection in Buffaloes (Bubalus Bubalis): Serological Detection by Using Two 
Different BoHV-1 Blocking ELISA. XXV  World Buiatrics Congress, July 6-11 2008.  
Budapest ,Hungary. 
  
6. Cuteri V., Nisoli L., Fruganti A., Romero Tejeda A., Attili A.  Evaluation of 
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